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I N T R O D U C T I O N  
The work described in this thesis has been carried 
out in Sheffield as a member of a team of physicians, 
physicists, and radiotherapists who together have been 
developing and using techniques for the application of 
radioactive iodine to the diagnosis and treatment of 
thyroid disease, and for the elucidation of various problems 
connected with normal and abnormal thyroid physiology, and 
with the pharmacology of iodine.
This work has been carried out under the overall 
supervision of Prof. E. J. Wayne, Professor of Pharmacology 
and Therapeutics in the University of Sheffield. Mr. G.
W. Blomfield, Medical Director of the Sheffield National 
Centre for Radiotherapy, has shared the responsibility for 
the therapeutic applications of the isotope.
The technical and physical aspects have been carried 
out by Dr. H. Miller, Chief Physicist, Sheffield National 
Centre for Radiotherapy, with the assistance of Mr. J. C. 
Jones, and co-operation with them has been exceedingly close 
at all stages of the study, and to them is due the credit 
for the development of some of the physical techniques that 
have been used to enable this study to be made.
I have been responsible, under the guidance of Prof.
E. J. Wayne, for the selection of patients, and the clinical 
application and interpretation of the results of the use
of radioactive iodine, both in the diagnostic and in the 
therapeutic fields. In this work I initially was working 
in eo-operation with Dr. J. F. Goodwin from May, 1948 to 
September 1949, and from June 1950, to June 1951, the 
clinical aspects were studied with the assistance of Dr.
G. Ansell.
The selection, study, and assessment of all patients 
on whom the tests have been performed, and of all patients 
treated with the isotope, has been chiefly my responsibility, 
and the long term study of all patients treated, and of most 
patients investigated, has been by me at the Endocrine Clinic 
of Sheffield Royal Infirmary, which I conduct on behalf of 
Prof. E. J. W$yne.
At various times, communications and demonstrations of 
aspects of this work have been made to Sections of the Royal 
Society of Medicine, the British Institute of Radiology, the 
Medical Research Society, the British Pharmacological Society, 
and to the Oxford Isotope Teqhniques Conference held in July 
1951, under the auspices of the Atomic Energy Research 
Establishment, Harwell.
Some of the work described in this thesis has been, or 
is being, published in the following papers, either by myself 
or jointly with the above mentioned collaborators:
(1). Macgregor, A.G.
Radioactive iodine in the diagnosis of thyrotoxicosis.
Brit. J. Radiol. 1950, 23,550.
(2). Macgregor, A.G.
The use of radioactive iodine in the diagnosis and
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and treatment of thyroid disease..
North Wing (Journal of Sheffield university 
Medical School) 1950.3.19.
(3)* Goodwin, J.F., Macgregor, A.G., Miller, H., 
and Wayne, E.J.
The use of radioactive iodine in the assessment 
of thyroid function.
Quart. J. Med. In press.
(4). Blomfield, G.W., Jones, J.G., Macgregor, A.G.,
Miller, H., and Wayne, E.J.
The treatment of thyrotoxicosis with radioactive 
iodine.
1. Brit. Med. J. 2* 373, f
2. Symposium of Oxford Isotope Techniques Conference, 
1951, H.M.Stationery Office. In press.
(3). Ansell, G., Macgregor, A.G., Miller, H., and 
Wayne, E.J.
The value of estimations of plasma radioactive 
iodine as an index of thyrotoxicosis.
Symposium of Oxford Isotope Techniques Conference, 
1951• H.M.Stationery Office. In press.
I should like to take this opportunity to express my 
gratitude and indebtedness to Prof. E. J. Wayne for permitting 
me to carry out this work, and for his general guidance and 
advice during the conduct of the study.
I wish also to thank Dr. H. Miller for his kindness and 
close co-operation throughout this study of thyroid function 
in health and disease, for without the help of himself and of 
his technical assistants, the difficulties inherent in the 
application of radioactive isotopes to the clinical problems 
of thyroid disease would have been most formidable.
Finally, I wish to express thanks and appreciation to 
my wife for her long-suffering patience, understanding and 
help during the course of this work, and the writing of 
this thesis.
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SECTION I
THE PHYSICAL BASIS OF ISOTOPE STUDIES 
The chemical properties of an element depend upon the 
number of units of positive charge, or protons that are present 
in the nucleus of the atom. This number is the atomic number 
of the element, but the nucleus of each atom contains, as well 
as the protons, a certain number of neutrons. The atomic 
^Lght of an element is constituted by the sura of the neutrons 
and protons. Physical investigation of the elements has 
shown that some of them exist in forms of different weight, 
although possessing the same atomic number and identical 
chemical qualities, and such similar forms are termed isotopes. 
Some isotopes are stable, these being the common form of the 
element, but others are unstable, and these are termed 
radioactive as they emit radiation of various types, termed 
alpha, beta or gamma according to the physical characteristics 
of that radiation. There are few naturally occurring radio­
active elements, such as radium, but radioactivity can be 
induced in most common elements by the bombardment methods of 
modern nuclear physics. Each radioactive isotope has its own 
physical characteristics, and can be readily distinguished by 
its own rate of radioactive decay and by the type of radiation 
produced. But whatever its physical characteristics, it 
behaves chemically in a fashion identical with the original 
element. A minute dose of such an isotope can therefore 
be administered to an animal or man, and its absorption and
-5-
subsequent metabolic fate followed by physical methods.
It can, moreover, be safely assumed that the behaviour 
of the stable form of the element is the same as that of 
the atoms that have been "labelled” with the radioactive 
isotope. At the same time, the radioactivity of suitable 
isotopes is so short lived that the dose of radiation to the 
living tissues into which it is introduced is negligible.
Ordinary iodine, whose atomic number is 53 has an atomic 
weight of 127, but one of its isotopes has 4 additional 
neutrons in its nucleus, and has therefore an atomic weight 
of 131; this isotope is unstable and, accordingly, radio­
active. This is the isotope I 131, now commonly used in 
studies of thyroid function, as it behaves chemically 
precisely as does iodine, I 127, itself. The disintegration 
of the isotope is due to the discharge of beta particles, or 
electrons, from the nucleus, which raises the positive charge 
on the nucleus to 54 protons, and the electrons surrounding 
the nucleus then rearrange themselves. The energy expended 
in the nuclear change is emitted as gamma radiation, a form of 
X-Rays. The beta radiation travels about 2.2 mm. only in 
tissue but it is used to measure the presence of the isotope 
in fluid samples - urine and blood, whereas the more 
penetrating gamma radiation is used to detect the isotope 
in the thyroid gland when a Geiger counter is placed above 
the patient’s necit. After the isotope has disintegrated 
it no longer behaves as does iodine, as in the process of
-6-
disintegration, it acquires the additional proton on its 
nucleus and becomes, in fact, another element, xenon.
The instrument at present used to detect the presence 
of a given radioactive isotope is a Geiger Counter, a 
sensitive device that records the ionisation produced each 
time radiation from a decaying atom of the isotope strikes 
the counter. Special electronic scaling circuits are used 
to count the number of such disintegrations, a number 
proportional to the amount of the isotope present. Such 
Geiger counters vary in their sensitivity, and their 
collimation, according to their particular design and 
physical characteristics. Some are designed to count fluid 
samples, some to count radiations emitted fromai isotope 
in a particular organ, and others are so designed that the 
area from which ionisations are counted is strictly limited 
so that the precise location of the isotope may be defined.
Soon after radioactive isotopes of iodine became 
available they were applied to the investigation of thyroid 
physiology, and subsequently have been widely used in the 
study and treatment of disease of the thyroid gland. The 
first investigations were made with I 128 by Hertz, Roberts, 
and Evans, (1938) but its short half life of only 25 minutes 
limited its use. Hamilton and Soley, (1939) used I 131, 
with a half life of eight days, and this has now become 
the standard agent used to study the pharmacological 
properties of iodine, the physiological role of the thyroid
gland in human metabolism, and its behaviour when affected
by disease#
-7-
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SECTION II
THE PHYSIOLOG-ICAL PRINCIPLES OF THE USE OF RADIOACTIVE IODINE
It la fortunate from the pc^ int of view of investigators 
with radioactive iodine that the thyroid gland is the most 
readily accessible and easily localised of all endocrine 
glands, for all observations upon it are correspondingly 
more easily performed than would be the case if it were 
situated as deeply as, for example, the suprarenal glands.
It has long been known that the gland is intimately 
concerned with the metabolism of iodine, and, although it 
weighs only about 0*05 per cent, of the total body weight, 
it contains over 20 per cent, of the iodine present in the 
whole body. (Best and Taylor, 1945). With radioactive 
iodine it has become possible to investigate the way in 
which the gland deals with any iodine presented to it by 
the circulation. The active principle of the thyroid 
hormone, thyroxine, contains iodine in its molecular structure. 
Much of the effort of the gland is directed towards intro­
ducing inorganic iodide, reaching it in the blood stream, into 
the benzene nucleus and thus producing thyroxine, which it then 
combines with a complex protein molecule to give thyroglobulin. 
The various steps of this process can be followed with the 
isotope and the speed with which they are accomplished, and 
the amount of the finished product, can be measured and used 
as an index to the grade of thyroid activity.
When radioactive iodine is administered, whether orally
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or intravenously, a large part of the dose is collected by 
the thyroid gland, which has the capacity of concentrating 
inorganic loulne to 10,000 oiuies the olooa level of 
circulating iodine, (Hamilton, 1942). That partof the 
iodine which does not enter the thyroid gland is excreted 
by the kidneys at a rate which, in the absence of renal 
disease, is fairly constant, and which depends upon the 
concentration of circulating iodine. In some cases the 
radioactive iodine collected in the thyroid gland and 
excreted in the urine only accounts for 85 to 90 per cent 
of the total dose administered: the remainder is mainly 
distributed throughout other body tissues, some is 
excreted in thefeeces, expired air, and sweat, (Kelsey, 
Haines, and Keating, 1949). There is, therefore, a 
constant state of competition between the thyroid gland 
and the kidneys to collect circulating iodine and any 
increase or decrease in thyroid activity is reflected in 
diminished or increased amounts excreted in the urine.
It is accordingly possible, by a study of the blood, 
urine, and thyroid gland content of radioactive iodine 
to study closely the fundamental processes that underly 
thyroid function, without the administration of quantities 
of iodine that might have a non-physiological, or a 
pharmacological action, upon the various phases of thyroid 
function.
-lo­
using the technique much information regarding 
thyroid physiology has been obtained, some of it new and 
much of it in confirmation of what had already been discovered 
by normal biochemical techniques.
The various steps in the cycle of iodine metabolism 
have been elucidated and the physiological aspects and 
inferences have been ably reviewed by Raben and Astwood
(1949) and Rawson (1949) and more recently in this country 
Bryant, Corbett, Honour, and Pochin (1950) and Myant and Pochin
(1950) have contributed new and fundamental information on 
the physiology of iodine and thyroxine metabolism.
These basic physiological studies provide an excellent 
example of the way in which radioactive isotopes can be used 
as a fundamental tool for medical research, and this is their 
most valuable role. This thesis is devoted to a discussion 
of the diagnostic and therapeutic applicatiors of one particular 
isotope, applications made possible because of preliminary 
detailed physiological studies. It must never be forgotten 
that despite its very considerable value as a diagnostic and 
therapeutic agent, the most valuable role of radioactive iodine 
is as a tool enabling us to probe yet further into the 
physiology of the thyroid gland, and to investigate the precise 
abnormalities of function that exist in various pathological 
conditions of the gland. It is by such basic and fundamental 
studies with the isotope that that knowledge will be gained
which will aid us to a closer understanding of the
mechanisms of disease, and thereby to a closer realisation 
of the means by which those diseases can be prevented or cured 
in their early stages*
SECTION III
THE DIAGNOSTIC APPLICATIONS OF RADIOACTIVE IODINE
(1). The Diagnosis of thyrotoxicosis
It was a natural sequel to the initial researches into 
thyroid physiology briefly described above, that attempts 
were made at an early stage to use the metabolism of radio­
active iodine as a test of thyroid function in order to 
provide a clinically applicable diagnostic test. Hertz, 
Roberts, and Evans in 1938, using I 128 with a half life 
of only 25 minutes were able to observe fundamental 
differences in thyroid function in thyrotoxie, as compared 
with normal individuals. This isotope was not, however, 
suitable for clinical use because of its short half life, 
and only with the isotope I 131 becoming available did 
practical diagnostic tests of thyroid function become a 
real possibility.
Muchwork has been carried out in various centres in an 
attempt to evolve with radioactive iodine a reliable test 
of thyroid function, and workers have approached the problem 
in different ways. The rate and extent of uptake of radio­
active iodine by the thyroid gland has been fully investigated 
by several groups of workers since Hamilton and Soley (1940) 
made the early observations on patients with various types 
of goitre. Keating, Wang, Luellen, Williams, Power, and 
McCon&hey, (1949) have assessed the value of such in vivo 
measurement of the quantity of radioactive iodine in the
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thyroid gland. Werner, Quimby, and Schmidt (1949a) defined 
the range of uptake in normal individuals, and the deviations 
which occur in thyroid disease, and Werner, Hamilton, Leifer, 
and Goodwin (1950) reviewed their experiences of 1,400 
estimations of thyroid gland uptake of radioactive iodine*
They concluded that the thyroid gland uptake of the isotope 
after 24 hours was a suitable technique for diagnostic 
purposes and at the Presbyterian Hospital in New York this 
test is being substituted for the basal metabolic rate 
determination as the initial routine laboratory screening 
procedure in the diagnosis of thyroid disorder.
Studies of the urinary excretion of the isotope have 
also been widely used as an indirect index of thyroid function. 
Keating, Power, Berkson, and Haines (1947) and Skanse (1949) 
made very careful analyses of the results obtainable by this 
method, and some workers in this country, (Arnott, Emery, 
Fraser, and Hobson, 1949; Mason and Oliver, 1949) have felt 
that it provides a useful and accurate test for the diagnosis 
of thyrotoxicosis, especially if the urinary output during the 
48 hours after administration of the isotope is subdivided 
into shorter periods. All workers agree, however, that the 
urinary excretion test alone does not differentiate clearly 
the normal from the abnormal in that important intermediate 
group of cases in which the diagnosis of thyrotoxicosis is 
clinically difficult and doubtful, that group, in fact, for
which there is the most need for a reliable objective index
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of thyroid function* McArthur, Rawson, Fluharty, and Means 
(1948) go so far as to state that a low urinary excretion 
of the isotope is a useful and valuable indication of 
thyrotoxicosis, but that intermediate degrees of excretion 
are of no diagnostic help*
In an attempt to obtain more useful and accurate guidance 
to the state of thyroid function, Keating, Wang, luellen, 
Williams, Power, and McConahey, (1949) have developed the 
conception of an iodide accumulation rate of the thyroid 
gland, as distinct from the absolute amount of iodide absorbed 
by the gland. After 3 years experience of the radioactive 
tracer technique in 790 patients this group of workers at 
the Mayo Clinic (Keating, Haines, Power, and Williams, 1950) 
felt that measurement of radioactive iodine accumulation by 
any one of several means was a highly efficient diagnostic 
tool for separating more than 90# of cases of exophthalmic 
goitre from normals, but that it was less satisfactory with 
regard to the presence or absence of hyperthyroidism in cases 
of adenomatous goitre.
The same workers, and Myant, Pochin, and Goldie (1949) 
have also suggested a thyroid clearance rate of plasma iodide 
analogous to the more familiar renal clearance rate of urea. 
The rate at which iodide isbeing absorbed by the thyroid gland 
is deduced from the curve of thyroid uptake obtained by 
external counting by a Geiger counter over the gland, the
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plasma concentration of radioactive iodine being determined 
simultaneously. Pochin (1950) has suggested that a simple 
clinical test that correlates closely with thyroid clearance 
of plasma iodine is the ratio of the counts obtained, one hour 
after the dose, over the thyroid gland to the counts obtainable 
at the same time over the thigh.
Foote and Maclagan (1951) have modified this latter test 
and have devised the “thigh-neck clearance11, being the Increase 
in neck counts per hour, divided by the maximum count obtained 
over the patient*s thigh. They have claimed that this test 
is suitable for routine use as a diagnostic procedure.
Other studies of thyroid function have been carried out 
to determine whether or not uptake into the gland within the 
first few hours only is a valid diagnostic test. Miller, 
Dailey, Holmes, Alexander, and Sheline^found that the initial 
rate of radioactive iodine uptake correlated well with the 
clinical evaluation of thyroid function, and Greer (1951) has 
demonstrated that uptakes at six and eight hours correlate 
quite satisfactorily with 24 hour uptakes.
The purpose of observations such as these is to determine 
the validity of tests which minimise the time for which the 
patient requires to be present for the test.
The “accumulation rate“ of Keating and his associates, 
an accurate and sensitive index of thyroid function, has the 
disadvantage that it does require in vivo observations over
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one or two days. Astwood and Stanley (1947) have devised 
a more empirical method of comparing the increase in thyroid 
radioactive iodine with time. They term this the accumulation 
gradient, and being a value obtained by plotting counting rate 
against the square root of time, they obtain a value in a 
few hours only. Keating, Haines, Power and Williams (1950) 
emphasise, however, that being an index expressed in arbitrary 
units dependent on many potentially variable factors, It is 
difficult for the values obtained for “accumulation gradient“ 
in one laboratory to be compared with those observed elsewhere.
It has been shown by Vanderliaan and Vanderlaan (1947) 
that the administration of 1 - methyl 2 - mercaptoImidazole 
prevents the conversion of inorganic Iodide to organic form 
and Stanley and Astwood (1948) have utilised this fact. They 
administer radioactive iodine within a few hours of a dose of 
100 mg. of this drug and then measure gland uptake of thd 
Isotope. They claim that this measurement of thyroid iodide 
content, as contrasted with measurement of total Iodine 
content, gives a very useful separation of hyperthyroid from 
enthyroid individuals.
Haigh and Reiss (1950) utilise a more complex test in 
which urinary output and Initial gland uptake are combined to 
give a factor which is said to have diagnostic value, and 
Fryers (1951) has found that the product of the rate of 
accumulation at 4 hours with the absolute amount accumulated
in the gland at that time gives a factor which discriminates
-17-
cleanly between thyrotoxic and normal Individuals.
Once again, however, these tests require observations 
over at least a day, and any test which can be completed within 
a few hours ia obviously preferable to a best which requires 
repeated or prolonged attendance.
All the tests mentioned so far have been measures of the 
capacity of the thyroid gland to concentrate iodide presented 
to it.by the circulation, but this is only one aspect of 
thyroid function, and it does not measure at all the release of 
thyroid hormone from the gland - nor its utilisation by the 
body tissues. The effect of the latter aspect is the function 
chiefly measured by the basal metabolic rate estimation, and 
the former function is measured by the chemical techniques of 
protein-bound iddine estimations. This represents a standard 
method of assessing thyroid function, and Bapport and Curtis
(1950) claim it to be the most reliable objective index of 
thyroid function. It has always been, ho?/ever, a difficult, 
laborious, and impracticable biochemical procedure, and, as such, 
unsuitable for routine application. The newer and simpler 
technique of Barker, Humphrey, and Soley (1951) may make it 
an estimation of more general applicability, but the adaptation 
of the isotope technique to this facet of thyroid function has 
already been a valuable addition to the diagnostic srm&inent&rlutB 
of the physician.
It is generally agreed that it is the pressnoo of inoroadod
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amounts of circulating thyroid hormone which is responsible 
for the clinical manifestations of thyrotoxicosis, and any 
method of detecting such an increase should be a useful index
of thyroid function. Furthermore, the work of Taurog and
and
Chaikoff (1948 ),/Leblond and G-ross (1949) in
animals has shown fairly conclusively that circulating thyroid 
hormone is probably thyroxine itslef, and Rosenberg (1951) came 
to the same conclusion in man. Taurog and Chaikoff, (1947) 
using a butyl alcohol extraction method for separating out the 
thyroxine, diiodotyrosine, and inorganic iodine fractions of 
the total plasma activity due to circulating radioactive iodine 
came to the conclusion that about 90% of circulating iodine is 
in the form of thyroxine. Leblond and Sue (1941) have 
shown that the diiodotyrosine fraction of the protein-bound 
iodine is rapidly metabolised and broken down in plasma to form 
inorganic iodide, and therefore an estimation of the protein- 
bound iodine, separated from the non-protein bound fraction by 
precipitation with trichloracetic acid is essentially a 
measure of the thyroxine content of the plasma. The use 
of radioactive iodine enables circulating thyroxine in the 
blood to be easily "labelled1 so that it becomes readily 
detectable and measurable. This estimation would be expected 
to give valuable diagnostic help, and it is, moreover, an 
estimation that can be made relatively simply.
McConahey, K eating and Power (1949) have studied fully 
the behaviour of radioactive iodine in the blood and found,
-19-
as was to be expected, that higher levels of protein-bound 
radioactive iodine were present In thyrotoxic than in normal 
Individuals, and similar findings were noted after 24 hours 
by Freedberg, Ureles, and Hertz (1949) and by Williams, Jaffe,
and Bernstein (1949). Clark, Moe, and Adams (1949) and sub­
sequently Sheline and Clark (1950), have utilised the speed 
of conversion of radioactive Iodine in&o protein-bound form 
as a diagnostic test, and they found that thyrotoxic patients 
had more than 50^ of the circulating plasma radioactive 
iodine in protein-bound form after 24 hours. This diagnostic 
test of thyroid function, using the isotope technique, has been 
found to correlate fairly well with chemical estimation of the 
protein-bound iodine (Sheline, Moore, Kappas, and Clark, 1951)
and it is, of course, a very much more simply performed
estimation.
Present investigation
It can be seen, therefore, from the diversity of tests 
that have been described, that although much work has been 
devoted to clarify the physiological behaviour of the 
thyroid gland and of thyroxine, lihere has been little 
agreement as to the most reliable and convenient way in 
which radioactive iodine may be used in the diagnosis of 
thyroid disease. There has always been a tendency for 
each group of workers to concentrate on zhe test which 
they have devised without making any especial effort to 
compare the tests with each other and so be in a position
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to assess their relative merits and value.
Accordingly, the purpose of the studies undertaken in 
Sheffield has been to assess with a variety of different 
measures of thyroid function, a group of patients of all grades 
of thyroid activity. It was realised that only by such a 
composite study would it be possible to devise and select 
for routine diagnostic purposes a test which was at the same 
time a valuable and reliable screening test for the diagnosis 
of thyrotoxicosis while being also convenient for both patient 
and physician. The emphasis was, therefore, on the invest­
igation of patients in whom there was a possibility of 
hyperthyroidism. The differentiation of normal from thyrotoxic 
gland function, is, moreover the aspect of thyroid physiology 
which most frequently gives rise to clinical difficulty.
Part nAlf - Definition of Standards
This covered the period from April 1948 through June 
1950, and during this period physical techniques were devised, 
perfected, and applied to the investigation of patients. The 
purpose of this study was to define the ranges of normality 
for a selected group of radioactive iodine tests of thyroid 
function, and to discover the deviations from normal that 
could be anticipated in association with hypothyroidism and 
hyperthyroid states.
From this study it was hoped that the most promising 
tests could be selected and applied to the investigation of
a further group of patients.
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Part uBn - General Application of Diagnostic Techniques.
This comprised the investigation of a further group 
of cases who were not all so fully investigated clinically 
and in whom an attempt was made to apply routinely certain 
of the tests of thyroid function which had been found in Study 
"A" to be the most reliable and helpful.
Part wAn - Definition of Standards
The group of patients studied contained patients of all 
grades of thyroid function, and it was decided, for the reasons 
already mentioned to carry out on each individual all those 
investigations which promised to be of diagnostic help, and 
initially a series of normal and thyrotoxic subjects was fully 
investigated. The severity of thyrotoxicosis was assessed 
using all the conventional clinical and laboratory methods 
that were available, and assigning to each patient a figure 
from one to four to indicate the degree of abnormality. Having 
thus obtained a standard for normal and thyrotoxic subjects 
the results were applied to a difficult intermediate group, 
the composition of which is discussed oeiow.
All the patients studied comprised a total of 94 
individuals of whom 16 were completely normal as regards 
thyroid function, and had no evidence of any other endocrine 
disturbance. Forty four patients were diagnosed as having 
primary thyrotoxicosis or toxic adenomata, the groups being 
composed of cases of all grades of toxicity, from mild,
borderline thyrotoxicosis, (Grade 1) to thyrotoxicosis of 
the most severe degree (Grade 4)*
These gradings are essentially arbitrary in nature 
and no high degree of accuracy is claimed for these figures.
They do, however, represent the final average opinion of 
at least three observers each of whom took into account every 
clinical aspect of the case. Cases in Grade 1 had least 
evidence of thyrotoxicosis, and some cases were only so classified 
after therapeutic trial with methyl thiouracil. The diagnosis 
was immediately obvious in cases in Grade 2, and the more 
severely affected patients were classified in Grades 3 and 4*
The "intermediate group" consisted of 30 patients in whom 
there was found no clinical evidence of toxicity after full 
and often prolonged study. Twenty five patients in this 
group presented features of past or present thyroid disorder, 
such as non-toxic goitres, simple adenomata, and patients 
with successfully treated or burnt out thyrotoxicosis.
There were also five patients who presented clinically with 
symptoms which are often seen in thyrotoxicosis. They, 
however, had no thyroid enlargement and an anxiety state 
was eventually diagnosed in each case as, after further 
observation, features became apparent which were inconsistent 
with a definite diagnosis of thyrotoxicosis.
The patients included in the intermediate group are 
therefore those who usually present the most clinical 
difficulties with regard to diagnosis. There was moreover, 
the additional factor that in the Sheffield area there is a
-23-
high incidence of non-toxic goi^tre with slight enlargement 
of the thyroid gland, and, accordingly, the clinical 
difficulties are thereby slightly increased when there is 
the concurrence of symptoms that may or may not be due to 
true thyrotoxicosis.
Four cases of myxoedema were also included in this 
study.
During the course of the study, many cases of thyroid 
carcinoma were also studied, but rather less fully, and the 
results are not included here, but, in some cases, discussed 
later. The results in no way conflict, as regards thyroid 
function as a whole, with the general statements that will be 
made later.
METHOD OF INVESTIGATION
All patients were admitted to hospital for in-patient 
care and investigation. The history was taken and 
physical examination carried out by three observers 
independently and the final diagnosis and grading were 
discussed. All cases except the normal group were followed 
for long periods in the out patient department, and in toxic 
cases the results of therapy were taken into account. It 
must be emphasised that the final decision as to whether 
an individual was clinically thyrotoxic or not was only taken 
after the most thorough sifting of clinical evidence that 
could be devised. In no case were any of the observations
using radioactive iodine taken into consideration in making
-24-
the final classification.
The collection of urine and blood specimens was very 
carefully supervised, as urinary samples especially tend 
to get mislaid if close watch is not kept on nursing staff.
Patients were fasting on the morning of test, and the 
tracer dose of 25 microcuries of radioactive iodine was 
administered orally and the container repeatedly washed out 
with water and subsequently monitored to ensure that all the 
dose was, in fact, taken. Patients were allowed to have 
lunch on the day of test, usually about 3 hours after the 
tracer dose had been given, while observations of the uptake 
of the isotope by the thyroid gland were being made. All 
urine specimens passed were collected, and subsequently 
aliquot samples of 10 ml. of each specimen were examined 
for their content of radioactive iodine.
At first estimations of blood activity were made on 
0.5 ml. samples, but this was found to be unsatisfactory 
because separate estimations of the protein-bound 
coneeritration could not be made with the technique used.
All estimations of plasma concentration included in this 
thesis were made on 20 ml. samples of blood withdrawn into 
a heparinised syringe. Samples of blood were usually taken 
at 1 hour, 3 hours, and 48 hours after ingestion of the 
radioactive iodine.
Figure 1. Method of abdication of shielded Geiger counter to measure 
gland content of radioactive iodine, (see text.)
--
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COUNTING TECHNIQUE USED
The amount of the active material taken up in the gland 
was assessed by Dr. H. Miller, Chief Physicist to the Sheffield 
National Centre for Radiotherapy, by means of a calibrated 
gamma ray counter housed in a substantial lead shield. Lead 
diaphragms were introduced to produce a suitable collimation. 
The whole counter with the associated preamplifier unit was 
mounted on the arm of a modified mobile X-ray unit stand so 
that it could be conveniently adjusted with respect to the 
patient. (Figure 1 ).
For calibration of the counter, measurements were made 
using a solution of radioactive iodine in a small glass phial, 
and by using glass models of the thyroid gland filled with 
an active solution.
In order to reduce the effect of absorption in the tissues 
a filter was introduced in front of the counter. This 
consisted of 1 mm. thickness of lead supported on a thin brass 
plate. The filter reduced to a negligible amount the effect 
of the soft component of the gamma radiation of the radio­
active iodine. It also had the effect of reducing to a small 
value the scattered radiation as measured by the counter.
The effective radiation centre of the gland in the patient
the
was obtained from a plot of/reciprocal of the square root of 
the counting rate against distance. In the majority of eases 
this effective radiation centre was approximately 2 cms. below 
the skin over the thyroid isthmus.
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In the build up curves in the gland, therefore, the 
calibration of the counter was deduced by measuring the 
concentrated source of radioactive iodine in its glass 
phial and this calibration was used after having deduced 
the effective radiating centre of the gland in question 
by the above method.
The effect of the 1 mm. of lead filtration in reducing 
the magnitude of the scattered radiation may be seen by 
comparing the method adopted by Myant, Honour, and Pochin, 
(1949). In their technique, using unfiltered radiation, 
the body tissues outside the immediate neighbourhood of the 
thyroid gland are screened from the counter but a large 
correction of the order of 21% for scattered radiation is 
necessary. In the Sheffield technique, devised by Dr. H. 
Miller, the filter used caused a reduction in the counting 
rate to a value of 60% of the unfiltered rate.
In plotting build up curves the usual practice was to 
count for a total of six minutes. This was divided into two 
periods of two minutes with the counter axis at a distance 
of 27 cms. from the skin over the isthmus, while between 
these counts one count was taken with a block of lead 
supported above the isthmus. The lead was 3.8 cms. thick 
and effectively cut out the radiation from the underlying 
gland leaving a background which fell slowly with time as 
the active material in the rest of the body was distributed 
and eliminated. The lead block was large enough in area
-27-
io eliminate radiation from the gland itself but it also 
cut out some radiation from the normal tissues of the neck. 
Since at peak take up, however, the blood concentration was 
generally less than !% per litre of plasma, the amount of 
activity in the normal tissues of the neck underlying the 
lead block was certainly less than 0*3% of "the ingested 
dose and was considered negligible. This was confirmed 
by the observed small counting rate over the thigh at a 
place where the cross section was roughly the same as the 
neck.
The actual counting rate for a dose of 20 jpc and for 
a 30% uptake under the Sheffield conditions was approximately 
350 counts per minute. The coefficient of variation (i.e. 
the standard deviation expressed as a percentage of the mean) 
for a particular point on the curve was therefore, generally 
less than 3%. It Is believed that the figures of peak uptake 
are correct to within 3% which Is sufficiently accurate for 
the purposes of this thesis.
Liquid samples were counted in the liquid counter devised 
by Yeal\9 (1948). As a standard a thousand fold dilution of 
the stock solution was used. All liquids placed In the 
counter had a few milligrams per litre of sodium Iodide 
introduced as carrier.
Urine concentrations over the first 24 hours were
adequate to give a small statistical error in counts of 5
minutes and the error in estimating the total urine output
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was influenced mainly by the adequacy of urine collection#
If no sample was lost the estimates of urln§ output were 
expected to be correct to within 5$• No figures are quoted 
when a urine sample containing an appreciable activity was 
lost.
Blood samples were taken into heparanised bottles and 
spun and the plasma was introduced into the counter directly.
A blood plasma concentration of 1$ per litre gave with the usual 
tracer drink of 25 pc, about 25 cts. per min. Counts of at 
least 10 minutes were made on these samples. The background 
count was around 12 counts per min# The statistical error in 
these results is much greater than in the other measurements, 
but it is estimated by Dr. H, Miller that the coefficient 
of variation of the individual blood measurements is less 
than 10$ except for concentrations less than 0.4$ of the 
ingested dose per litre.
The estimation of the protein-bound Iodine in the plasma 
was carried out by the technique used by Ohaikoff, Taurog* 
and Reinhardt, (1947), as follows? 10 ml. of the plasma 
were precipitated with 30 ml. of 10$ trichloracetic acid.
This was centrifuged and the supernatant liquid poured off#
The precipitate was then shaken with a further 30 ml. of 
trichloracetic acid and the whole cnetrifuged again# After 
a repetition of this last procedure the precipitate was 
dissolved in 2N NaQH/ and Its activity estimated# It was 
generally possible to dissolve the precipitated proteins
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from 8 ml. of plasma in 10 ml of N^aOH Counts on protein- 
bound speeiments were normally carried out for at least 15 
minutes and were subject to somewhat greater errors than on 
plasma specimens.
RADIATION HAZARD TO PATIENTS
The use of radioactive isotopes exposes both patients 
and workers with the isotopes to a certain amount of 
radiation, and it is important to consider whether or not 
any adverse effect is likely to follow their use.
It is essential that the dose of the isotope used for 
diagnostic tests be kept to a minimal level, but rather 
different considerations apply for such tests to those 
which are applicable to patients undergoing treatment 
with large doses of the Isotope. The possible hazards 
of such therapy are considered in the Therapeutic section 
of this thesis.
It is recognised that in the use of doses of radio­
active iodine of the order of 25 - 30 microcuries the dose 
of ionising radiation given to the thyroid gland itself 
is not negligible though the dose given to the rest of the 
body may be considered so. (Outside the thyroid this dose 
is everywhere less than 0.3 roentgen). If the uptake in 
the gland is 50$ and the rate of biological elimination has 
a half life of 8 days the dose given to a gland of normal 
size is approximately 35 r following a tracer drink of 25fio 
In Sheffield the doses given to the glands of the oatients
have varied widely over a range of roughly 10 r to 100 r.
The International Recommendations on Radiological 
Protection recently issued by the International Commission 
of Radiological Protection (1951) state that the maximum 
permissible dose received by radiation workers exposed to 
external radiation should be 0.3 r/week, even when the 
irradiation is confined to a particular organ or tissue.
It is not known how far doses in the tolerance region can
be considered as cumulative, and whether it is legitimate
for example, to consider a dose of 15 r in any one year 
on a limited volume of tissue as equivalent in radiation
danger to 0.3 r per week over 50 weeks.
The International Commission on Radiological Protection 
does not make firm recommendations regarding the maximum 
permissible exposure to internal radiation. For occupational 
exposure a maximum permissible amount of radioactive iodine 
in the body is 0.3 microcuries as this would give a dose rate 
in the gland of 0.3 r per week.
In order to minimise the necessary dose, Dr. H. Miller 
in Sheffield has undertaken experimental work designed to 
give increased sensitivity to measurements of plasma protein- 
bound iodine samples. In the meanwhile, however, and with 
the equipment at present available, it was felt that tests on 
normal people should be made only once and the "Normal” 
group in this series is as small as could give reasonably 
representative figures.
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It has been considered justifiable to use 30 microcuries 
in cases where there are reasonable grounds for suspecting 
thyroid disorder, but the tests have only rarely been 
repeated on a particular patient in less than 1 year 
except where radioactive iodine therapy has been intended 
to follow the investigation.
The practice of other workers has varied considerably 
as to the dose considered reasonable for diagnostic tests 
of this type, though some work has suggested that tracer 
drinks should not normally be greater than 10f$ (Arnottf 
Emery, Fraser, and Hobson, 1949; Tait, Cook, and Worsnop, 
1951). This would give a dose of about 15 r which, 
averaged over 1 year, is about the recognised maximum 
permissible dose for occupational exposure.
It has frequently been pointed out that radiation doses 
of the same order as those given in these tests are given 
routinely to limited regions of the body in mapy X-ray 
diagnostic techniques. This is especially true of the 
skin in normal screening procedures, (Martin, 1947 ; Braestrup 
1942) The skin dose of radiation following an average 
barium meal examination is 45 r. The effects of such 
occasional exoosures of this magnitude in normal diagnostic 
work of this kind have not so far been considered as of a 
serious nature. Although the lack of comment upon such 
exposures by diagnostic radiologists does not justify the 
procedure if there is an appreciable risk, It has at least
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Figure 2. Curves showing the radioactivity present in the thyroid 
gland, urine, and plasma of a normal person after injection of 
radioactive iodine.
>
?
- 32-
never been convincingly demonstrated that such exposures 
have ever been followed by any detrimental effects.
RESULTS
As has already been outlined under the section dealing 
with the physiological background of the use of radioactive 
isotopes, it was early found by other workers that the 
thyrotoxic gland had a very much greater avidity for iodine 
that the normal gland, and consequently the curve of gland 
activity when plotted against time was seen to vary very 
considerably between the different types of gland function. 
This alteration in the capacity of the gland to concentrate 
iodine has an effect on the curve of blood activity of 
radioactive iodine, and this latter curve is also affected 
because the thyrotoxic gland also turns out very appreciable 
quantities of thyroxine which, after the administration of 
the isotope, becomes radioactive and so readily detectable.
The curves in typical normal and typical thyrotoxic 
gland function are contrasted in Figures 2 and 3, and 
the blood curves are considered separately in Figure 4*
In normal gland function (Figure 2) the iodine is 
steadily concentrated by the thyroid gland, the balance 
being progressively excreted by the kidney. Myant, Pochin, 
and Goldie (1949) have shown clearly that the renal 
excretion rate of iodine is proportional to the plasma 
concentration of radioactive iodine, and furthermore, that
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the renal clearance rate for plasma radioiodide has the same 
value of about 30 ml. per minute both in normal and in 
thyrotoxic subjects. Any variation of thyroid clearance 
rate, ..is. therefore reflected in smaller or larger amounts 
of radioactive iodine being excreted in the urine. In the 
great majority of normal persons a greater amount of the 
isotope is excreted in the urine in the first day than is 
absorbed into the thyroid gland. As will be seen from the 
detailed results in Part f,A M of this Section, most normal 
persons concentrate between 30$ and 55$ of the dose in the 
thyroid in the first 24 hours and excrete over 35$ of it. 
Furthermore, the gland absorption is gradual, and not 
complete until at least 24 hours, and the curve may rise 
after that time.
In a thyrotoxic patient, on the other hand, there is a 
very much higher and more rapid gland uptake, usually 
exceeding 60$, and conversely a low urinary excretion.
There is also, characteristically, a progressive fall in 
the thyroid activity after the peak point of the curve, a 
fall that is due to the release from the gland of the 
radioactive iodine that has become bound into thyroxine, 
and, as such, discharged into the circulation. In Figure 
3, the corresponding blood curve is superimposed onto the 
other curves of gland and urine activity, and it can.be 
seen that the secondary rise in plasma activity corresponds 
with the fall in gland activity.
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figure 4. Curves showing plasma activity in selected typical cases 
after administration of radioactive iodine.
A. Total plasma activity, thyrotoxicosis.
A1. Plasma protein-bound activity, thyrotoxicosis.
B. Total plasma activity, normal individual.
Cf Total plasma activity, myxoedema.
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The typical curves of blood activity in myxoedema, normal, 
and thyrotoxic gland function are compared in Figure 4.
After the initial rise in plasma concentration following upon 
absorption of the radioactive iodine, Lhere is a fall of 
concentration, and this renects the disappearance of 
radioactive iodine as iodide from the blood into the thyroid 
gland, urine and other sites of disposal. The rate of this 
disappearance of radioactive iodine from the blood reflects 
changes in thyroid function, being more rapid in thyrotoxicosis 
than in normal subjects, and conversely, less rapid in 
hypothyroidism.
Blood estimations during this phase are of definite 
diagnostic value, and the suggestion of Myant and Pochin 
(1949) that the isolated observation of plasma activity 
at 2 hours after administration of radioactive iodine is 
a valuable test is also based on utilising the fact that the 
disappearance of iodine from the blood is very rapid in 
thyrotoxicosis. They noted that the plasma activity in 
normal persons was at this time always more than, and in 
thyrotoxicosis less than 2%, of the administered dose per 
litre of plasma.
In toxi^/cases, therefore, a minimal level of plasma 
activity is reached at an early stage, corresponding to 
the earlier peak of thyroid absorption, whereas normal 
function is characterised by a more prolonged and gradual
fall in activity.
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The next phase of the curve of radioactive iodine 
concentration in plasma is that which indicates the appearance 
in the blood of iodine in protein-bound form, probably chiefly 
as thyroxine. This phase starts much earlier in thyrotoxic 
individuals than in normal persons, and iodine in protein- 
found form can occasionally be detected in thyrotoxic individuals 
at a very early stage, within two or three hours and its 
continued discharge into the blood is shown by a marked 
secondary rise in the level of plasma activity. This rise 
is difficult to detect by present techniques in normal 
persons; in any case, it is of much less degree, and it is 
most unusual to find more than a negligible amount of radio­
active iodine in protein-bound form present in a normal 
person before the third or fourth day. It was felt, therefore, 
that 48 hours would be the best time at which to measure plasma 
activity, both the total activity and that due to protein- 
bound iodine. Any activity then present should be due chiefly 
to protein-bound activity in toxie persons; in normal 
persons activity should be minimal because by that time the 
greater part of the administered dose should have been 
excreted in the urine or held in the thyroid gland from 
which the output of thyroxine has not yet begun.
The detailed data derived from the study of patients 
included in Part 1 A” are presented in Appendices I - V, 
with full particulars of the results of each test relating
to every case. The results in Part ”A,f are summarised in
KEY TO HISTOGRAMS.
□ NO RM A L, CASE 3. f 16 CASES.)
J36
22
INTERMEDIATE GROUP CASE 36. 
NON TOXIC GOITRE. 
THYROTOXICOSIS IN REMISSION. 
ANXIETY STATE.
( 3 0  CASES.)
ALL CLINICALLY GRADED AS NON TOXIC.
r 33 CASES OF THYROTOXICOSIS. >> 
THYROTOXICOSIS OR TOXIC ADENOMA. CASE 56. „  CASES QF TQX|C ADENOMAJ
GRADE.
MILD THYROTOXICOSIS.
2. DEFINITE TOXICITY.
3. MODERATE SEVERITY. 
- 4 .  MOST SEVERE TOXICITY.
GRADE 3.
£97 MYXOEDEMA. CASE 97. ( 4  CASES.)
Explanation of symbols used in Figures 5 - 12. Case numbers refer 
to numbers in Appendices 1 - 7 .
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Table I. It was not always possible to carry out 
satisfactorily all investigations in every case, and when 
technical faults or inaccuracies in the collection or 
assessment of samples of blood or urine have made results 
unreliable they have been omitted.
The distribution of results of the investigations in all 
patients so tested is also presented in the form of histograms 
representing the results of patients* basal metabolic rate 
estimations (Fig.5); thyroid gland uptake of the radioactive 
iodine at the peak point of the collection of iodine by the 
gland (Fig.6); and at 24 hours after the dose was administered 
(Fig.7); the distribution of the times which elapsed until 
half the peak uptake was reached in each case (Fig«8); the 
urinary excretion of the isotope in bulked samples covering 
the first 24 hours (Fig.9); the thyroid clearance rates 2 
hours after the dose was given, or at the time when the half 
peak uptake value was reached by the gland, whichever was 
the higher (Fig.10); the total plasma activity 48 hours 
after the dose, (Fig.11); and the plasma activity due to 
the protein-bound fraction of the 48 hour sample of plasma 
(Fig.12).
To assist recognition of individual cases so that 
reference can be made to the Appendices and to other Figures, 
the symbol representing each case bears the case number of 
the patient, and, additionally, symbols of thyrotoxic 
patients carry a figure representing the clinical grade
of toxicity.
BASAL METABOLIC RATE. °/o OF NORMAL.
1_____________________________________________________
Figure 5. Distribution of results of basal metabolic rate estimations.
-37-
BASAL METABOLIC RATE
This estimation, (Fig.5*) was carried out by the 
Douglas bag method or with a spirometer and the figures 
quoted are the mean of two or more consistent results.
The test was not carried out on all patients included in 
the nofmal group (Appendix 1), since we know that with our 
technique normal individuals may give readings lying between 
20 and - 20$. On this basis 13 thyrotoxic cases out 
of 39 on which the test was performed, or 33$ of the total, 
had ’’normal” basal metabolic rates and included in that number 
are 5 of moderately severe or very severe degrees of toxicity 
(Gases 59, 67, 71, 72, and 88). In addition three cases 
of non-toxic goitre or anxiety state had basal metabolic 
rates in excess of 20$. These figures serve to confirm 
the generally accepted view that an estimation of the basal 
metabolic rate is of only doubtful value in differentiating 
between thyrotoxicosis and other conditions, when there is 
clinical doubt regarding the diagnosis. It Is of interest 
that Keating, Haines, Ppwer, and Williams, (1950) in their 
study of the value of radioactive iodine as a diagnostic aid 
found that, taking the Mayo Foundation standard deviation of 
the basal metabolic rate at any age as 6.9$, then 51$ of 
their euthyroid patients had values outside the normal range, 
i.e. outside a range of 13 to -13$ ( I 2®-).
Bartels (1950), moreover, found the basal metabolic rate 
to be below 20$ in 3$ of a series of 1,000 thyrotoxic patients
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of radioactive iodine.
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and in some cases a normal basal metabolic rate was found 
in the presence of severe thyrotoxicosis, a finding which 
was also noted in this series, (Gases 59, 67, 71, 72, and 88). 
Furthermore, a raised rate occurs in many conditions other 
than thyrotoxicosis, such as heart failure and pyrexia, and 
the presence of an apparently raised rate in some cases of 
anxiety state is not an uncommon finding.
This figure, therefore, suggests agreement with those 
who regard an estimation of the basal metabolism as of little 
help in doubtful cases rather than with Simpson (1948) who 
states that a normal basal metabolic rate is never found in 
thyrotoxicosis.
All the results of basal metabolic rate estimations are 
presented so that the value of this traditional investigation 
in eases of suspected thyrotoxicosis may be compared with the 
results of the more specific tests of thyroid function using 
radioactive iodine.
THYROID GLAND UPTAKE
The gland uptake of radioactive iodine at the peak 
value is shown in Appendices I - Yv and is charted in Figure 
6. In the normal group the uptake was in the range of 
21 to 54$ of the administered dose with a mean of 38$.
The intermediate group had a somewhat similar range, with 
a mean of 48$ with the important exception that there were 
eight cases which had a peak uptake of over 55$ (Cases 17,
20, 22, 31, 36, 37, 44, and 46). These eight cases overlap
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Figure 7. Distribution of estimations of thyroid gland uptake 24
hours after a dose of radioactive iodine.
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with the toxic group of 44 patients, all of whom had peak 
uptakes of 56% or greater, the highest uptake in the series 
being 92% in two cases, (Cases 71 and 79) and the mean of the 
group 74^* All the toxic group had uptakes greater than any 
recorded in the normal group, and three of the four patients 
with myxoedema had the lowest uptakes recorded.
The uptake by the gland at 24 hours, (Fig.7) shows the 
same pattern of distribution as at the time of peak uptake, 
but even more overlap is apparent between the toxic and 
intermediate or normal categories. No less than twelve 
intermediate group or normal cases appear in the same overlap 
area in the figure as 21 toxic eases, but the greatest overlap 
occurs in the 50 - 60% range. In many toxic cases there is 
a drop in the 24 hour values as compared with the peak uptakes, 
and this fall in the amount of iodine retained in the gland is 
because of its conversion into thyroxine and transfer into the 
blood, a transfer known to correspond with a rise in the 
activity of plasma by that time. The fall in gland activity 
nay be very considerable in some cases, as in Case 64 where 
a peak uptake of 75*5$ had diminished to 55% by 24 hours, and 
in Cases 71 and 79 where the drop was in each case from 92% 
to 72%.
Gland uptake after 24 hours does not give as true an 
indication of the avidity of the gland for iodine as does 
the peak uptake, but it enables us to compare these values
with those published by Werner, Quimby, and Schmidt, (1949a)
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in one of the largest series so far reported. The Sheffield 
range for normal uptakes is 19 - 53% which compares with a 
range of 7 - 49$ in the American workers’ series of 57 
normal controls. Whereas, however, only 6 (10$) of their 
cases had uptakes greater than 35$, there are 5 patients 
(35$) in the normal group in this series with uptakes of 
this order. We believe these differences to be significant 
and to be possibly connected with the known lack of iodine 
in the Derbyshire area (Murray, Ryle, Simpson and Wilson, 1948) 
It is recognised that thyroid glands with low iodine content 
from any cause have an increased avidity for iodine, and 
Leblond and Mann (1942) showed that continued dietary iodine 
deficiency led to increased thyroid iodine collection.
There is little overlap between the patients with 
thyrotoxicosis and the normal controls, in respect of their 
peak and 24 hour uptakes, but there are eight cases in the 
intermediate group with no evidence of toxicity who had either 
anxiety states or non-toxic goitres, and who had uptakes of 
56$ or greater and so overlapped with the toxic group. In 
the group studied by Werner and his associates no less than 
40 out of 97 thyrotoxic patients had uptakes within the limits 
observed in their control subjects. If in their series 40$ is 
taken as the upper limit of normal then only 4$ of their 
normal cases fall in the toxic range, but 11$ of their 
toxic cases then lie in the normal range.
Luellen, Keating, Williams, Berkson, Power, and McGonahey
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(1949) also noted that some euthyroid patients with nodular 
goitres may at times collect more radioactive iodine in their 
thyroids than other euthyroid subjects, and they concluded 
that adenomatous goitres, especially large ones,ougbt not to 
be regarded as entirely normal in function even in the 
absence of clinical hyperthyroidism. Werner, Quimby, and 
Schmidt (1949) and Myant, Pochin, and Goldie (1949) also 
mention cases of non-toxic goitre with uptakes of this 
order; the former workers have noted, in a series of 
patients investigated when in remission of hyperthyroidism as 
a result of various types of treatment, that the iodine uptake 
often continues at an elevated level, despite the regression 
of symptoms and the return of the basal metabolic rate to 
normal. Findings such as these, as well as similar 
observations,, discussed-later, made following effective 
therapeutic doses of radioactive iodine# show that unusually 
high uptakes of radioactive iodine by the thyroid gland may 
exist without there being overactivity of the gland as judged 
by other criteria.
The peak and 24 hour uptake of patients with toxic 
adenomata was, in general, lower than that of the group 
with diffuse thyrotoxicosis, the mean peak uptake of the 
adenomatous group being 6A% as compared with a mean of 
78$ in the remaining toxic cases.
The equipment was not sufficiently collimated to 
decide whether or not the activity in the adenomata was
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significantly higher than that in the surrounding thyroid 
tissue, a finding discussed by Means, (1949) with regard 
to the function of isolated thyroid adenomata. In five 
cases, however, (Cases 86, 87, 89, 92, and 95) it did 
appear that the greatest amount of activity present in 
the gland was concentrated in the palpable adenoma.
Two of the patients in the toxic group, Cases 74 
and 75, with two of the lowest uptakes, 51%> and 61% 
respectively, had previously had thyroidectomies, and 
the lesser amount of active thyroid tissue may be related 
to their smaller uptake of radioactive iodine, despite 
their undoubted toxicity.
It would appear, therefore, that where the volume 
or mass, of hyperfunctioning thyroid tissue is small, 
such as where there are nodular recurrencies after partial 
thyroidectomy, or vihere there is toxicity due to the presence 
of an adenoma, then the absolute amount absorbed by the gland 
as a whole is of less diagnostic value than in patients where 
the thyrotoxicosis is due to diffuse enlargement of the gland 
as in typical Graves disease. This accords well with the 
observation of Keating, Haines, Power, and Williams, (1950) 
that no matter by what technique radioactive iodine concentration 
in the thyroid gland is measured, there is a significant 
overlap with the euthyroid range, and that radioactive iodine 
tracer tests, as carried out by them were of limited value
for indicating the presence or absence of hyperthyroidism
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in cases of adenomatous goitre.
A further point of interest that emerged from the 
investigations was that a relationship appeared to exist 
between the severity of the thyrotoxicosis as assessed 
independently on clinical grounds, and the uptake of iodine 
by the gland. In the histograms of peak uptake (Fig.6) 
and 24 hour uptake (Fig.7) it can be seen that there is 
a tendency for cases of Grade 3 and 4 toxicity to fall 
among the upper values, and Grades 1 and 2 to fall among 
the lower values of the toxic group. If the "mean grade" 
of severity is estimated for each column of toxic cases in 
Fig. 2, there is a gradual rise of severity from a "mean 
grade" of 1.6 in the group with a peak uptake of 56% to 
60#, through successive "mean grades" of 1.7, 2.6, 2.8,
3.1, 3*6, and 2.9 to a "mean grade" of 4 in the 91$ to 
95$ column. A similar rough correlation exists with the 
24 hour uptake figures.
TIME TO HALF PEAK UPTAKE
The rate of uptake of radioactive iodine by the thyroid 
gland is a measure of thyroid function which has been 
assessed in various ways by different groups of workers.
A very simple measure of the rate at whieh the iodine is 
being removed from the blood by the thyroid is the time 
which elapses until half the maximum gland uptake has been 
ahhieved, (the time to the half peak value, Myant, Pochin, 
and Goldie, 1949) and observation of this value by serial
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in vivo measurements of gland activity after administration 
of a tracer dose shows clearly that thyrotoxicosis is 
characterised by a vsry much more rapid "time-to-half-peak1 
than occurs in normal individuals. The values in this
investigation are shown in Fig. 8. In this series all
thyrotoxic patients had times which were over an hour 
shorter than 14 of the 15 normal controls. This index 
is a measure of the slope of the curve of uptake of 
radioactive iodine into the gland, and is affected by the 
rate of absorption of the oral dose of radioactive iodine, 
a variable which has induced some workers to use the 
intravenous route for administering their tracer doses 
(Bochin, 1950). The longest value, in the toxic group, 
Case 62, was in a patient who, through a misunderstanding 
received a light breakfast some two hours previously.
Some of the other more prolonged values are undoubtedly 
related to variable rates of absorption from the bowel, 
quite apart from the rate at which the thyroid gland 
absorbed circulating iodide.
The mean time to half peak of the whole toxic group 
is 74 minutes, that of the intermediate group 215 minutes, 
and of the normals 293 minutes. Myant, Pochin, and Goldie 
(1949) quote values of 280 minutes for their control group 
and 54 minutes for their toxic group.
There is, however, a significant overlap between the
groups, and a half-peak time between 100 and 150 minutes
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can occur in a normal, intermediate group, or toxic case.
It will be noted that many of the cases in the intermediate 
group which occupy positions in the overlap zone are in a 
similar position in the gland uptake histograms.
The slow rise of gland uptake and the uncertainty 
regarding the time when maximum absorption is attained, 
makes it difficult to assess this value in myxoedema, 
but the times probably fall within the normal range.
24 HOUR URINARY EXCRETION
The values for the 24 hour urinary excretion of 
radioactive iodine show a distribution which is the reverse 
of that of gland uptakes, toxic cases excreting the least 
amounts, (Pig.9). There is a very considerable overlap 
when bulked 24 hour urine excretion figures are used, no 
less than 11 normal or non-toxic patients having urinary 
excretions within the same ranges as 14 patients with 
thyrotoxicosis, the overlap arising in the range of 20% 
and 35% of the administered dose. Marinelli, Quimby and 
Hine, (1948) found the test more useful if the excretion 
over the first 6 hours was neglected, and Mason and Oliver, 
(1949) and Arnott, Emery, Fraser, and Hobson, (1949) further 
subdivided the 48 hour period. In Sheffield, however, we 
restricted our observations to 24 hour samples and agree 
with these latter workers that it is not a practical prodedure 
to apply the mathematical analysis of Keating, Power, Berkson,
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and Haines, (1947) as a routine in all cases, because of 
the obvious unreliability of urine collection especially 
in the female, and because of the intrinsic inaccuracies 
of the method. Skanse, (1949) points out that the extent 
of overlap between thyrotoxic and euthyroid patients varies 
considerably in different studies and probably depends to a 
great extent upon the type of case studied. As with 
thyroid gland uptakes, some patients with non-toxic 
goitres may have'urinary excretions of radioactive iodine 
which are intermediate between those found in normal 
controls and those which are typically thyrotoxic, and 
the test in some, such as those descrioed by Fraser,
(1949) may actually suggest frank thyrotoxicosis. ‘ Fraser 
points out that there is a trend t©wards a less abnormal 
urinary excretion as the diagnosis of thyrotoxicosis becomes 
less certain, and this trend is evident in Fig..9.
THYROID CLEARANCE: RATE 
Another index of the rapidity of uptake of iodine 
by the thyroid gland is the plasma iodide clearance rate, 
a measure of the volume of plasma completely cleared of 
iodide by the thyroid in unit time. The clearance rates 
of the subjects in this investigation are charted in Figure 
10, and show mean clearances of 24, 36, and 297 ml. per 
minute in the normal, intermediate, and toxic groups 
respectively. There is not, however, the clear cut 
separation between toxicity and normality described by
iyant, Poehin, and Goldie, (1949). The highest normal 
clearance rate was 46 ml./minute, but higher clearance 
rates were found in seven subjects in the intermediate 
group, with a reading of 71 ml./minute in Case 36, and 
clearances of the order of 20 - 80 ml./minute only in 
eight of the 31 thyrotoxic persons in whom the calculation 
was possible, all except one, Case 73, being patients with 
toxicity of Grades 1 and 2. The remaining thyrotoxic 
cases all had clearances in excess of 80 ml./minute, the 
value quoted by Pochin (1950) as being, in his experience, 
that below which Graves disease is not probable. Keating, 
Wang, Luellen, Williams, Power and McConahey, (1949) quote 
four cases of exophthalmic goitre with thyroid iodine 
clearance rates below 70 ml. per minute. The 
figures in this series would support these workers’ findings 
that it is possible to detect comparatively low clearance 
rates in the presence of thyrotoxicosis, and the absence 
of such low readings in the series of Myant, Poehin, and 
Goldie (1949) is probably due to the absence of cases with 
only slight degrees of thyrotoxicosis. On the evidence 
of this series, there does not apuear to be a clear cut 
separation between the thyrotoxic and the euthyroid 
individual, but a gradual gradation between the two.
It can be seen that there is a tendency for Ghe most severe 
cases to have the highest, and the mildest cases the lowest, 
thyroid clearance rates, with rates higher than normal
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oceurring in a selection of patients with anxiety state 
and non-toxic gaitre.
It is possibly of significance that four of these 
eight cases had toxic adenomata rather than diffuse 
thyrotoxicosis, and patients with toxic adenomata usually 
have clearance rates very considerably lower thafa those 
found in diffuse thyrotoxicosis; this is undoubtedly 
because the probable higher clearance rate of the hyper­
functioning adenoma is being masked by the relatively 
normal rate of the rest of the gland. Estimations of 
clearance rate have, therefore, a similar inability to 
indicate toxicity in this group as have the gland uptake 
figures, already discussed. They have, however, the 
advantage that they can be accurately calculated without 
knowledge of the actual dose given.
PLASMA ACTIVITY ESTIMATIONS 
All the above results are in essence, indices of 
the capacity of the thyroid gland to concentrate iodide 
presented to it. Very soon after starting the work it 
was felt that a more physiological measure of thyroid function 
would be an index of the ability of the thyroid to convert 
iodide into thyroxine and discharge it into the circulation.
It therefore became necessary to determine at what time the 
most valuable diagnostic information would be obtainable 
from an observation of plasma activity, both its total 
activity and that due to iodine in protein-bound form.
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Figure 12. Distribution of estimations of protein-bound plasma 
activity 48 hours after a dose of radioactive iodine.
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Preliminary work on a number of patients produced 
the data already discussed in connection with Figure 4 
and, as mentioned there, subsequent observations were 
only made at the 48 hour time.
The results are shown in Figures 11 and 12. An 
estimation of the total activity alone provided a rough separat­
ion between the toxic individuals and those with normal 
or intermediate thyroid function. The cases in the 
overlap zone were chiefly those with low clearance rates 
and consequently more delayed absorption of circulating 
radioactive iodine by the gland. Nevertheless, there is 
almost a ten times difference between the mean of 0.16 per 
cent of the dose given per litre of plasma for the normal 
and intermediate groups (combined) and the mean of 1.53 per 
cent per litre for the toxic group. Values in excess of 
0.7 per cent per litre were usually found in thyrotoxicosis,
"And seldom, if ever, in euthyroid persons, but lesser 
amounts than 0.7$ per litre were not incompatible with 
a diagnosis of thyrotoxicosis.
When the protein-bound activity was measured, (Fig.12) 
a very sharp demarcation became apparent between the toxic 
group on the one hand, and the intermediate and normal 
groups on the other. In the absence of toxicity only 
two eases had a protein-bound activity in excess of 0.2$ 
per litre, and 31 cases had values less than 0.1$ per litre. 
Conversely, only two cases which had been definitely graded
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as thyrotoxic had values less than 0,2% per litre, whereas 
all the remainder tested, (24 cases) had values in excess 
of 0,4% per litre. This test, therefore, was manifestly 
a useful diagnostic aid, and experience shows that if a 
greater amount than 0,4% of the dose per litre of plasma 
is present in the plasma at 48 hours in protein-bound form 
the patient should be regarded as a case of thyrotoxicosis; 
values below this are only occasionally found in the presence 
of thyroid overactivity.
The higher amounts of activity present in protein- 
bound form were found in those patients, (cases 64, 65, 76, 
and 79) with a rapid fall in the thyroid gland uptake after 
the peak value had been reached. This principle can be 
further emphasised by comparing the biological half life 
of the radioiodine in the thyroid gland with the 48 hour 
protein-bound plasma activity. In Figure 15 these values 
afre charted for all the cases in Part nAfl of this series 
where both are known, and it can be seen, with only a few 
exceptions that the higher values of protein-bound plasma 
activity are in those cases with the shorter biological 
half life. it is apparent, therefore, that as well as 
being an index of the amount of circulating thyroxine,
48 hour protein-bound plasma activity is also a measure 
of the rapidity of conversion of administered radioactive 
iodine into thyroxine and its discharge into the 
circulation.
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While this work was in progress, several observers 
reported somewhat similar observations. They have usually, 
however, chosen to make their observations 24 hours after 
the dose, and their work has either centred upon a study 
of the rate at which radioactive iodine becomes protein-bound, 
or, alternatively, of the absolute amount present. Clark,
Moe, and Adams, (1949) and Sheline and Clark, (1950) found 
that patients in whom at 24 hours more than 50$ of the total 
plasma activity was due to protein-bound iodine were thyro­
toxic. (The data presented here would confirm this finding 
for the 48 hour time.) They required, however, doses of at 
least 50 to 200 microcuries of radioactive iodine for their 
observations. Freedberg, Ureles, and Hertz, (1949) demon­
strated that after 24 hours, protein-bound radioactive iodine 
reached higher levels in thyrotoxic fcatients than in normals, 
but found that, at that time, the total plasma activity did 
ndt sharply separate toxic from normal thyroid function. 
Williams, Jaffe, and Bernstein, (1949) also reported that 
in thyrotoxicosis the total and protein-bound radioactive 
iodine activity was above normal after 24 hours and they 
suggested, although they did not show, that a sharper 
separation might be achieved if longer intervals elapsed 
before the specimens were collected.
McConahey, Keating, and Power (1949) have noted that 
the levels of protein-bound radioactive iodine were higher 
in thyrotoxic than in euthyroid individuals. They also
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no ted that all the circulating radioactive iodine was 
protein-bound in thyrotoxic subjects after a period which 
averaged 46 hours, but that in normal individuals the average 
time required was about four days, a finding which re­
emphasised the value of making plasma activity observations 
after 48 hours, a time chosen by us in Sheffield as the
result of observations of plasma activity followed over a
period of time, (Figure 4).
It should be emphasised that none of the above workers 
have carried out in the same individuals investigations both 
of thyroid uptake of radioactive iodine and estimations of 
plasma levels of protein-bound activity. It is only by 
such a comparative and comprehensive survey that the relative 
merit of the different tests can be assessed, and that the
value of any particular test can be viewed in true
perspective.
CONCLUSIONS DERIVED FROM PART "A"
After consideration of the facts demonstrated in the 
histograms which illustrate the results of Part "A", several 
conclusions can he drawn.
Firstly: An estimation of the basal metabolic rate alone 
does not appear to be of value in separating thyrotoxic 
from non-toxic individuals when the clinical decision 
regarding the diagnosis is difficult.
Secondly: The peak gland uptake of a tracefdose is a
reasonably accurate measurement of the avidity of the gland
for iodine, and that by it the great majority of thyrotoxic
individuals can be separated from the non-toxic persons.
In this respect it is far superior to the value obtained
at 24 hours which so often, in thyrotoxic patients, may be
very appreciably lower than the value of the peak point of
the curve, because of the rapid turnover in the gland of the
Yts
radioactive iodine, and tke discharge as thyroxine.
Thirdly: Measurements of 24 hours urinary excretion 
are equally valueless in diagnosing the clinically difficult 
cases. it can be seen from Figure 9 that all except 1 of 
the clinically less certain thyrotoxic cases, those of Grade 
1 severity, had 24 hour urinary excretions in the overlap 
zone between 20% and 35%. This particular index did not, 
therefore, appear to have real clinical value.
Fourthly: Similarly, measurements of the time to half
peak uptake value were not of great value in the doubtful 
cases, and, from the practical point of view, this index
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requires as much work on the part of the observer for its 
recording as did the peak value itself, already shown to be 
more specific.
Fifthly: Thyroid iodide clearance rates can be seen to be 
of value in one particular fashion, that a high clearance 
rate, over 80 ml. per minute, appeared to indicate toxicity 
although kwer rates did not exclude it. This value however, 
has the advantage that precise knowledge of the dose given 
is not necessary, as its calculation depends on its relation 
between the plasma concentration and the rate of gland 
uptake. Provided, therefore, that serial in vivo gland 
counts are taken on either side of the time at which the 
blood sample is obtained, then the index can be readily 
obtained.
Sixthly: Total plasma activity after 48 hours gives a 
reasonably good separation of the toxic from the non-toxic 
patients, above and below a value of about 0.6 - 0.7$ per 
litre. Further, the 48 hour protein-bound plasma activity 
gives a surprisingly good separation, sharply differentiating 
the two types of cases in a way which closely corresponded to 
the very careful clinical assessment of the patients.
From the diagnostic viewpoint therefore, three tests 
stood out as being the most valuable.
(1). The Peak gland uptake.
(2). The thyroid iodide clearance rate.
(3). The 48 hour protein-bound plasma activity.
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PART t!B H
G-ENERAL APPLICATION OF DIAGNOSTIC TECHNIQUES 
Scope of Investigation
This immediately succeeded Part "A”, and its primary 
objective was to extend the studies already carried out, and 
to apply the selected tests routinely to further cases.
In practice, in about half the patients, as full 
investigations were performed as in Part f,Afl, but for the 
purpose of analysis, all results have been presented with 
respect to the selected tests only.
The secondary objective of Part f,Bn was to determine 
whether any one test alone could be adopted as suitable 
for a single routine diagnostic test, divorced from the 
support afforded by the simultaneous performance of the 
other tests.
For this purpose it is of course highly desirable 
that any selected test must have several characteristics.
(1). It must be simple in the extreme.
(2). it must make minimal demands upon patients time 
and upon the time of physician and of technical 
staff.
(3)• It must, if possible, be such that the minimum 
number of patients require to be more fully 
re-investigated later because of equivocal 
results in the original tests.
(4)* Its requirements should be economical of 
hospital space, equipment, and facilities if 
it is to be suitable for general adoption in 
centres other than a well equipped teaching 
hospital.
(5). It must be readily applicable to outpatients.
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With these considerations in mind, the peak uptake 
value obviously had several disadvantages, as frequent serial 
invivo gland counts are necessary to be able to define a 
peak value, and this was undesirable and impracticable for 
a routine test. On the other hand, thyroid iodide clearance 
rates can be measured accurately within a reasonable space of 
time after giving the dose, and, .although, as with peak 
uptake values, in vivo counting techniques are required, with 
all the necessary equipment, the test is obviously readily 
applicable to out-patients.
The 4S-hour protein bound plasma activity test, on 
the other hand, fulfils all the criteria necessary, and, on 
the face of it, appears to be ideal. Its reliability had, 
therefore, to be tested fully, and this was done by comparing 
it directly with the other indices and with the careful 
clinical assessments of the level of clinical thyroid function.
First of all, however, it became necessary to find an 
alternative test of the amount of iodide absorbed in the gland 
which gave as accurate an estimate of gland activity for 
iodide as the peak value. This meant a selection of a time 
at which the gland uptake for all cases could be assessed and 
at which time the content of the gland would bear some tnie 
relationship to that reached at the peak of the curve. Times 
after the peak are obviously unsuitable, for the reasons
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discussed with regard to 24 hours uptakes.
The gland content 4 hours after an oral dose was, 
therefore, selected for the analyses of the results of these 
investigations, as it was a time manifestly suitable for use 
with outpatients, and which was sufficiently late after 
administration of an oral tracer dose to eliminate any 
variables of gland absorption.
Accordingly, the 4-hour uptake in all the cases in­
part A was analysed and compared with the peak uptake. The 
results are ^ described in Figure 14 where the. open circles 
include both "normal*1 and intermediate group cases, all being, 
from the diagnostic point of vie?/, "non-toxic11. Solid circles 
indicate thyrotoxic cases.
It can be seen that the overlap zone between toxic 
and non-toxic gland function lies, with respect to peak uptake, 
between the vertical lines representing a range from 55?* to 
70% (as in Figure 6); within this range are some 16 thyrotoxic 
and some 7 or 8 non-toxic cases. On the other hand, the 
overlap zone for 4 hours gland uptakes, between the short 
horizontal pair of lines, includes only about half as many 
cases, the chief ones excluded being the thyrotoxic cases 
with low total peak gland uptakes. The reason for this is 
obviously that in thyrotoxic function iodide absorption is 
more rapid as well as being greater than normal, so that glands 
that possibly may not absorb a very high amount at the peak 
of the curve, absorb what they do concentrate very quickly, 
so that by only 4 hours after injection they have absorbed
- 58-
almost as much, usually, as they are going to absorb in all.
The result is, therefore, that their relatively high 
absorption after 4 hours more clearly differentiates them 
from non-toxic individuals than even the low peak uptake.
I t can be seen, therefore, that whereas 4 hour 
uptakes give essentially the same information as peak uptakes, 
they are preferable to it as being slightly more specific in 
their differentiation of the types of function, and they are, 
of course, very much more readily measured.
Accordingly, the results of the cases investigated 
in Part B were all analysed with respect to three indices,
(1) the 4 hour gland uptake, being an index 
of the absolute uptake and avidity., of 
the thyroid for iodine.
(2) The thyroid iodide clearance rate about 
1 hour after an oral tracer dose being
an index of the rate of iodide absorption 
into the gland, in contrast to the amount 
absorbed.
(3) The 48-hour protein bound plasma activity, 
being an index of the capacity of the gland 
to synthesise thyroxine and discharge it 
into the blood.
For the purpose of the presentation of the results 
of this investigation, the results of all the cases observed 
in part B (details in Appendix VI and Vll) have been combined -in 
Figures 15-20, with the results obtained from the patients J-n 
Part A. It is felt that thereby additional information can
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be derived from the pooled results, information which 
allows us to compare carefully the three tests under review, 
and lets us balance their relative advantages and dis­
advantages .
In these figures the black symbol^ indicate
thyrotoxic patients, of all grades of severity (see Figures
/
15-17), and the open circles indicate non-toxic patients, 
the "normal" and "intermediate" group cases part A being 
combined with all the non-toxic cases in the second series 
of investigations in Part B. From the non-toxic cases, 
those patients who at any stage raised in the mind of one 
or more observers the possibility that he or she might be 
thyrotoxic have been extracted and are represented in the 
figures as the "Doubtful" section of non-toxic patients.
These cases were, however, all finally clinically classified 
as non-toxic despite the initial clinical impression.
The "Definite" cases were those about whose normal thyroid 
function there was no doubt, and there was unanimous 
agreement clinically that they were not, in fact, thyrotoxic.
It can readily be appreciated that it is the 
differentiation of the "Doubtfulj1 non-toxic" category from 
the "Grade 1, thyrotoxic" group which is the most difficult 
and important clinically, and any valuable routine test of 
thyroid function must be able to separate them fairly 
accurately.
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The following remarks, therefore, apply to the
interpretation of the data provided by the combined groups
and
of cases, representing a total of 94 normal persons/patients 
classified as non-toxic, and 83 patients with one or other 
of 4 clinical grades of severity of thyrotoxicosis.
4"Hour Gland Uptake
The results of the analysis of the gland uptake 
figures after 4 hours are shown in Figure 15. It is again 
apparent, as occurred in t-:.e original group of cases, that 
there is roughly a gradual gradation in the result of this 
test that parallels the clinical gradation in severity 
throughout all cases.
Nevertheless, the 40% uptake level in 4 hour readings 
appears to separate fairly well the non-toxic from the 
thyrotoxic individuals, the latter almost invariably having 
a 4 hour uptake greater than this j the few exceptions were 
in cases of lesser degrees of severity. In nearly a dozen 
cases, however, uptakes of greater than 40% were encountered 
in non-toxic persons. These higher uptakes usually 
occurred In patients with a goitre, and were just in that 
group of people in whom the clinical differentiation was 
most difficult; some non-toxic nodular goitres had very 
high 4“hour gland uptakes, in particular cases 111, 134,
141 and 149.
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This pooled information might, therefore, he said 
to show that 4-hour uptake values only misdiagnose:; a 
thyrotoxic patient very rarely, but that some non-toxic 
patients react, with regard to this particular test of 
tnyroid function, as though they were thyrotoxic.
Thyroid Clearance Rates
The results of the thyroid clearance rates are 
similarly presented in Figure 16. It was found, in 
agreement with Pochin (1950), that thyrotoxicosis is 
usually associated with clearance rates over 80 ml - per 
minute, but on the other hand, this large group of cases 
included an appreciable number, 17% of total thyrotoxic 
cases, with clearance rates between 30 and 80 ml. per minute, 
rates commonly encountered in non-toxic persons. Furthermore, 
only 38$ of these eases with low clearance rates were of the 
mildest, Grade 1, severity, the remainder being quite 
definitely toxic and two cases were moderately severe.
^The extension of this study to the cases of Part B reveals
*
3 cases, Nos.101, 121 and 134, with rates over 90ml. per 
minute, the level of thyroid function in two of them being 
indubitably normal.
Therefore, just as 4 hour uptakes chiefly misplaced 
non-toxic cases with high uptakes, this experience in the 
combined groups of cases suggested that tho chief defect 
of clearance rates is that some toxic cases with low rates
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behave with this test as if they were non-toxic.
48-hour Protein-Bound Plasma Activity
Figure 17 summarises the results in all cases of 
the estimates of protein-bound plasma activity. Even with 
the increase in the number of cases beyond those studied in 
part A of this investigation, and represented in Figure 12, 
there still remains a very sha^r demarcation between the
two groups. All the thyrotoxic cases in which the test was
\
performed except 4 (6%) had activities in excess of 0.4% per 
litre, and no non-toxic eases at all fell into this toxic 
range, giving an overall accuracy of 9&% in the assignments 
of the case to the correct clinical category, taking a 
concentration of 0.4% per litre as the division between non­
toxic and thyrotoxic gland function. It should be noted that 
three of the four toxic cases with low or negligible 
activities were only of Grade 1 severity, and the possibility 
of an error in clinical classification should always be borne 
in mind. Throughout this work the essential base line has 
had to be the eventual clinical classifications, but it is 
conceivable that in some cases the objective test may be the 
more accurate. After all, the eventual value of any objective 
test'must be its ability to make diagnostic decisions easier, 
and so make it possible for the clinician to omit lengthy 
and time consuming clinical assessments.
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Concluslons derived from Part B
It appeared therefore, that if these three tests 
4-hour uptake, thyroid clearance rates, and 48 hour protein- 
bound plasma activities, were directly compared over a large 
number of cases, it could be concluded that:
(1) 4 hour uptakes gave an overall accuracy of 
diagnosis, in agreement with the baseline of 
clinical assessment of 93%'t
(2) Thyroid clearance rates gave an overall 
accuracy of 91% and
(3) 48 hour protein-bound plasma activity
estimations gave an accuracy of 9Q%.
Furthermore, it appeared that there was, as had been
previously suspected, a gradation in the clinical severity of
the cases which roughly corresponded to the gradation in the
results of the tests that measured uptake of iodide into the
gland, whether of absolute amount, or of rate of uptake. This
can be well seen by study of Figures 15 and 16 and of; Figure 18,
where 4-hour uptake and thyroid clearance rates in all cases
where both were observed, are related to each other. It can be
seen that the vast majority of high uptakes were associated with
high clearance rates, and that this association occurred in
thyrotoxic patients. Conversely, low uptakes and rates were
found together in most non-toxic patients. There was, however,
a considerable overlap in as much as a number of non-toxic and
thyrotoxic cases had high uptakes with low clearance rates, the
high uptakes correctly placing the thyrotoxic cases,
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Figure 19. Relation of 4 hour gland uptake to 4S hour protein-bound 
plasma activity levels.
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and the low clearance rates correctly placing the non-toxic 
cases.(Oases in top left hand corner of figure). Only 
3 cases, two non-toxic and one toxic, had both tests at 
variance with that which was expected from their clinical 
category.
Therefore, the supportive value of carrying out two 
tests simultaneously became less if both tests were those 
measuring amount or rate of uptake, high uptakes associated 
with low clearance rates being a feature common to both 
thyrotoxic and non-toxic persons. There was manifestly some 
other factor which more closely related with clinical 
classification than either of these indices, and the experience 
in this study would suggest that this factor is adequately 
represented by a measure of the protein-bound plasma activity 
which is, as already mentioned, merely labelling the level of 
circulating thyroxine, and as such would be expected to be a 
more accurate diagnostic index.
This can be clearly seen if the 48-hour protein-bound 
plasma activity values are directly compared with each of the 
other two indices. In Figure 19 are plotted the 4-hour uptake 
figures against the 48 hour protein-bound plasma activity.
It can be clearly seen that high uptake figures are usually 
associated with high levels of protein-bound activity, and 
conversely, but that in the case of the non-toxic cases with 
high uptakes, their low protein-bound activities accurately
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places them in the non-toxic category. Similarly, the 
cases with low and borderline uptake figures are shown, 
where toxic, to be accurately classified by their raised 
levels of protein-bound activity, the only exceptions being 
the four toxic cases with negligible activity in the plasma.
If this maneouvre is repeated with respect to the 
clearance values, Figure 20, it can be seen that high 
clearance rates are usually associated with plasma protein- 
bound activity levels well within the toxic range, except 
in the case of those non-toxic patients with high clearance 
rates. There are, in fact, shown to be non-toxic by their 
low protein-bound activity. More striding, however, is 
the way in which those cases considered to be toxic, but with 
low clearance rates, are shown to be toxic by their high 
plasma values. Once again the four thyrotoxic patients with 
low values are the anomalous cases. All four of these 
cases had 4-hour uptakes over 40%, two had clearance rates 
well outside the normal range, and two had clearance rates 
around 80 ml. per minute. It is possible that the latter 
two are wrongly classified clinically, and the former two 
are the only cases in the series where the 4b-hour protein- 
bound plasma activity test has failed definitely to give a 
positive indication of existing thyrotoxicosis.
Reliance on this test alone, therefore, on the basis 
of the cases here represented, would give more consistently 
accurate and diagnostic information than any other test alone.
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It would appear that no non-toxic cases would be suspect of 
being thyrotoxic, and only the exceptional thyrotoxic case 
would be misdiagnosed. It manifestly has very many advantages 
over any test involving the collection of urine, or any test 
where gland, or gland and thigh, counting is required, as such 
tests tend to be time consuming both to staff and patient, and
to require an accurate geometrical set up of the equipment used.
The fact that the patient does not need to come into 
contact with any counting equipment, and that only two short 
visits are required, one to administer the oral dose of 25-30 
micro^curies, and another for a few minutes 4d hours later 
for a vene-^puncture, makes it an ideal and simple test for 
routine application as an in-patient or out-patient diagnostic 
technique. It is, in fact, therefore potentially applicable 
in a fashion which renders an objective test of thyroid 
function as easily performed as a Wasserman reaction, or any 
diagnostic investigation where all that is required from the 
patient is a sample of blood.
It was felt to be worthwhile, therefore, to test this
latter statement by applying the method in practice, as an
an
isolated diagnostic index in/attempt to provide an easy means 
whereby other clinicians could be afforded diagnostic assistance.
Accordingly, with the co-operation of a physician in 
Nottingham G-eneral Hospital, over 50 miles from Sheffield,
No
Table II
Results of Outpatient tests of AS hour 
plasma activity estimations at 
Nottingham General Hospital.
AB hr. activity 
Total Protein bound
%llitre
1 1.23 0.9S
2 0.6 0.6
3 3.5 2.8
1.7 1.3
given
Toxic 
Probably toxic 
Very toxic
Toxic
Clinical Impression 
at Nottingham
"Mild thyrotoxicosis"
"Probably toxic"
"Probably not toxic" 
(Exophthalmos, palpi tati o ns, 
sweating, nervousness)
"Not now toxic, 
although was so in 
195 0"
5 0.62 0.56 Probably toxic “Probably not toxic"
6 0.19 0.14 No it-toxic "Anxiety state"
7 0.8 Not done ' Possibly toxic HFrobably thyrotoxi co si s"
8 1.62 1.0 Toxic "Probably thyrotoxic"
9 0.1 0.1 Non-toxic "Normal"
- 67-
Dr. H. Miller and I arranged to despatch once per week, 
diagnostic doses^of radioactive iodine which were administered 
to patients in Nottingham. Blood plasma samples withdrawn 
48 hours later were returned to Sheffield for assay of 
their protein-bound plasma activity. The results are shown 
in Table XI.
It can be seen that the predicted diagnosis made from
a
the activites found in the samples agreed'well with the 
clinical diagnosis made in Nottingham and forwarded subsequently 
to Sheffield with detailed case reports. It is felt that the 
cases where the results are inconsistent, represent probable 
errors in clinical assessment in Nottingham rather than 
misleading results of the radioactive iodine test. Later 
clinical evaluations in the light of this test will almost 
certainly be revised.
Discussion of Value of Tests_using Radioactive Iodine in the 
Diagnosis of Thyrotoxicbsls
The diagnosis of thyrotoxicosis can usually be made on 
the basis of history and physical examination alone. There 
are, however, many cases in which additional information is of 
great value and the problem of overactivity of the gland is 
always raised if the patient has a goitre and especially if 
there is in addition tachycardia. All patients who have had 
thyrotoxicosis in the past, and who have been treated, present 
difficulties in assessment. It is well known too, that many 
patients with an anxiety state may stimulate thyroid disease, 
in some respects.
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The estimation of the blood cholesterol is 
acknowledged to be of little value in hyperthyroid states 
although it is of value in hypothyroidism, and Sheffield 
experience agrees with that of Peters and Man, (1950) and of 
Bartels, (1950). An estimation of the basal' metabolic rate, 
on the other hand, can be of some value if d0ne in hospital 
and in duplicate, but on balance the experience of jaffe and 
Ottomaan, (1950) who found only a 67% agreement when they 
correlated the clinical findings with estimations of basal 
metabolic rate, is fairly general and emphasises the frequent 
lack of value of the test where there is clinical doubt.
(Cf. Figure 5).
Rapport and Curtis, (1950) claim that the chemical 
estimation of the protein-bound iodine in the plasma is the 
best measure of thyroid function, and while this is probably 
the case, the technical difficulties involved in carrying out 
the determination accurately are much greater than in making 
observations with radioactive idoine, and this will remain 
the case until simpler methods, such as that of Barker, 
Humphrey and Soley (1951) are available.
Observations with radioactive iodine are not difficult 
to perform, once the basic equipment has been obtained, and 
where possible several types of test should be simultaneously 
carried out. If, however, it is desired to carry out routine 
observations on a large number of cases or to investigate them
as outpatients, it becomes necessary to select one, or at the 
most two, of the tests.
As assessment or  the total amount of radioactive 
iodine that is absorbed by the thyroid gland, or excreted 
by the urine, indicates the inorganic iodide retaining capacity 
of the thyroid gland, a capacity which is known to be 
considerably influenced by previous administration of iodine 
or by the exhibition of drugs which have an effect on thyroid 
functions, such as thiocyanate, the thiouracil group, or 
resorcinol,(Bull and Fraser, 1950); furthermore, the capacity 
of the gland to retain the iodine may alter very considerably 
within a short time after cessation of administration of the 
drug. Nevertheless, iodide retaining capacity is a function 
of the thyroid gland which is very greatly increased in 
conditions where there is clinical evidence of increased 
thyroid activity. Measurements of the degree and rate of 
this uptake, therefore, provide an index of thyroid activity 
which, in the majority of cases, separates those persons with 
normal function from those with hyperthyroidism or with 
hypothyroidism. The degree of overlap, however, is such 
that the test is of less value in tnejdifficult intermediate 
group of cases where there is a possibility of mild 
hyperthyroidism, or, alternatively, where the symptoms may 
be due to a non-toxic goitre with superimposed anxiety state.
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Experience with observations of the uptake after a 
few hours only, however, appear to show that this is possibly 
of greater value than the observations of peak uptake, and 
4-hour uptakes are certainly very much preferable to 
observation of tne uptake after 24 hours, an index accepted 
by several clinical centres as suitable for routine adoption 
as a routine diagnostic screening test. (Werner, Hamilton, 
Leifer and Goodwin, 1950; Jaffe and Ottoman, 1950).
Recently, Miller, Dailey, Holmes, Alexander, and 
Sheline, (1951) have shown that the absolute uptake into the 
gland at any particular time between 2 and 7 hours after 
administration of the dose is of considerable diagnostic value; 
Kriss (1951) has demonstrated that the gland uptake one hour 
after an intravenous tracer dose is able to differentiate 
sharply between euthyroid and hyperthyroid individuals, and 
that it also is greatly superior to 24 hour uptakes in rapidity 
of execution, and improved.diagnostic accuracy. Both these 
observations are in agreement with the findings of this series 
that gland contents at an early part of the uptake curve haye 
considerable diagnostic utility.
Urine excretion of radioactive iodine is subject to 
the same objections as gland uptake, with, in addition, the 
added difficulties inherent in the collection of urine samples. 
It is moreover, very much less suitable as a diagnostic 
procedure applicable to outpatients, and the only merit is the 
relatively small dose of radioactive iodine necessary for its
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performance. Skanse (1949) however, professes great faith 
in the diagnqtie accuracy of the results obtained from 
analysis of 48 hour excretion samples of urine.
Annott (1951) claims, moreover, that it is possible 
to devise a technique and organisation that permits of the 
application of the method of Arnott, Emery, Fraser and Hobson 
(1949), to routine outpatients in a General Hospital. The 
method involves the collection of urinary samples in divided 
time intervals over 48 hours, but equivocal and undiagnostic 
results are obtained in 10# of cases. Additionally, moreover, 
there is continual uncertainty regarding the accuracy of 
the urine collection, an accuracy which is necessary if the 
results are to be properly interpreted in the light of past 
experience. Experience in Sheffield, and in most American 
centres, is rather suggestive that the simplicity of urinary 
techniques is not repaid by sufficient: diagnostic accuracy ,
with the results obtained by them.
Of the figures which give evidence of the speed of 
uptake of iodine by the gland the best is probably the thyroid 
clearance rate, Myant, Pochin, and Goldie (1949), but Keating 
Wang, Luellen, Williams, Power, and McConahey,, (1949), found 
that low clearances may occur in cases of undoubted thyrotoxicosis 
and the experience in the series here described is similar•
Pochin, (1950) has suggested a simple method of 
obtaining a measure of thyroid clearance rate by taking the 
ratio of counts obtainable over the thyroid to the counts over
- 72-
the thigh one hour after a dose of radioactive iodine. This 
method, though simple, is less accurate than, and has the same 
defects as the measurement of clearance rates using the method 
which involves the taking of blood samples and the same criticism 
applies to that of Foote and Maclagan (1951) who measure thigh- 
neck clearance.
The methods so far discussed give figures which are 
related to the iodine concentrating and retaining capacity of 
the thyroid gland. The measurements next to be considered are 
related! to the amount of circulating thyroxine and would appear, 
a priori, more likely to give figures which would correlate well
with the deviations of the individual from normal thyroid
function. This is found in fact to be the case. The total 
plasma activity correlates well and the protein bound activity 
agress very well with the clinical assessment of patients. The 
most striking difference between these results and those obtained 
by all the other methods of assessment with radioactive iodine 
is the way in which nearly all the normal and non-toxic group 
of patients fall in the normal range.
There is no doubt that measurement of the protein-bound
activity of the plasma 48 hours after the administration of a dose 
of radioactive iodine is the figure which best separates the 
clinically toxic from the non-toxic group of individuals. This 
separation is essentially between those patients who require 
treatment and those who do no1* as there must undoubtedly be a
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oomplete "spectrum" of thyroid activity running from complete 
myjoedema to severe thyrotoxicosis.
The sensitivity of the test at present is not, however,
activity
such that measurements of the 48 hour protein-bound plasms/can 
differentiate between patients in the normal and "intermediate” 
groups studied in Part A of this thesis. There is such a 
slight difference between the groups if mean tiptake figures 
are compared in the two groups (Table II) and this is not 
reflected in the protein-bound activity estimations. It is 
likely that with improved counting technique it may be possible, 
with the same dosage used in this study, to demonstrate that 
there Is in fact, a gradation of protein-bound plasma activity 
at 48 hours throughout the i,ntermediate”group. It is 
understandable that a patient who had had a previous thyroid­
ectomy, and present?lclinically with symptoms suggestive of 
thyrotoxicosis, should have some slight disturbance of thyroid 
function even if it is not of sufficient degree to constitute 
frank thyrotoxicosis. The results of the present study have 
shown that the presence of the clinical manifestations of 
thyrotoxicosis are in fact associated with protein-bound plasma 
activity at 48 hours usually in excess of 0.4% per litre, but, 
with improvements in counting technique it can be anticipated 
that it will become possible to separate out lesser degrees 
of abnormality of thyroid function.
Case
No.
Table III
Results, typical of many others, showing 
reproducibility of radioactive iodine 
tests of thyroid function.
FIRST
TEST
4 hr. gland 
uptake
Toxic cases
165 79
175 46
1.0. 79
A.O. 82
J.B. 57
Non-toxic cases
36 37
125 is
70 dose
SECOND
TEST
IS
AS
79
84
68
36
21
48 hr. protein-bound 
plasma activity 
FIRST SECOND
2.4 
0.67 
0.9
1.5
1.2
negligible
negligible
dose/litre
2.7
0.57
1.2
1.5
1.2
negligible
negligible
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Radioactive iodine tests of thyroid function are 
essentially reproducible in a given individual, provided that 
the test is carried out on successive occasions under the same 
conditions. We have not felt justified in repeating 
observations on individuals with demonstrable normal thyroid 
function, except in a few exceptional cases. Observations can, 
however, justifiably be repeated in thyrotoxic patients who 
may be subsequently going to receive therapeutic drinks of 
radioactive iodine, and experience with such patients shows 
that, with regard zo 4 hour uptake figures and 4b hour plasma 
protein-bound activity levels especially, the results are 
closely reproducible, within the limits of biological 
variability and the statistical accuracy of the physical 
techniques used.
Typical repeat test results are shown in Table 111, in 
a selection of 5 thyrotoxic and 2 non-toxic patients, the results 
being representative of many other similar observations that have 
usually been made in connection with studies of the pharmacological 
effect of drugs &n thyroid function.
The few cases which gave anomalous and borderline results 
in the 4b hours plasma activity test must now be considered and 
the relevant information has been collected in Figure 21.
Cases 87 and 180 showed results in all the tests which fell into 
the overlap zones, and it is possible that these patients 
clinically assessed as only grade 1, were, in fact, not suffering 
from thyrotoxicosis.
TOXIC CASES WITH
48 HR. RB. PLASMA ACTIVITY
UNDER 0-4 %  I LITRE
NON-TOXIC CASES WITH 
48 HR. RB. PLASMA ACTIVITY 
OVER 0 3 %  / LITRE
CASE N°
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Figure 21. Distribution of results of tests of thyroid function in 
some anomalous and border line cases. (see text.)
-75-
Cases 61 and 166 fell into the toxic group both clinically 
(grade 3) and in respect of peak and 4 hour gland uptake and 
clearance rate. There may well have been an error in asssy 
of protein-bound activity in these instances.
All three of the non-toxic cases with 46 hour protein- 
bound plasma activities of appreciable degree, but less than 0.4% 
per litre, had results in the other tests that were confirmatory 
of their non-toxic clinical states.
It is our experience that when a case was really difficult 
to classify clinically, we found subsequently that the iodine 
uptake figures and clearance rates were equally unhelpful. 
Nevertheless, the 46 hour protein-bound plasma activity estimation, 
being a functional index of circMating thyroid hormone, and quite 
separate from other indices measuring iodine uptake, would appear 
to assist in the further classification of these difficult cases, 
for in many such doubtful cases it is the only index tnat agrees 
with the ultimate clinical diagnosis, a diagnosis frequently only 
reached after many months.
In agreement with other workers, recent previous 
administration of iodine containing compounds, especially those 
used for diagnostic radiological procedures such as cholecystograms 
was found to depress iodine uptake figures considerably and 
' render a radioactive iodine test invalid. All cases included in 
this series had not had any previous iodine administered. 
Nevertheless, in two cases not included in this series, clinical
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frank toxicity was associated with elevated 48 hour plasma 
protein-bGund activity values, ?/hereas the gland uptake figures 
fell within the normal range. Both cases had had recent 
iodine administered to them, one in the form of a cholecystogram 
four weeks previously, and the other large doses of inorganic 
iodide within the previous three weeks. Keating, Haines,
Power, and Williams, (1950) found that the depressant effect 
of iodine seldom lasted longer than two weeks, but that a 
cholecystogram might depress gland uptake of iodine for many 
months. The Mgestion of thyroid extract also depresses 
iodine uptake very considerably (Skanse and Riggs, 1948).
Furthermore, the renal excretion rate of iodide is
proportional to the plasma concentration of radioactive iodine,
and the renal clearance rate has the same value in normal and
Pochin
in thyrotoxic subjects lyanp' and Goldie (1949). In the 
presence of renal disease, however, when renal excretion of 
the isotope is delayed, it is possible to obtain abnormally 
high uptakes of radioactive iodine into the gland, thus 
possibly giving the impression of overactive thyroid function.
In such circumstances there is no rise in the total or protein- 
bound plasma activity at 48 hours, and, by this criterion, 
toxicity would not be suggested.
RADIOACTIVE IODINE TESTS OF THYROID FUNCTION 
BEFORE AND AFTER SUCCESSFUL TREATMENT.
R A D IO A C T IV E IO D IN E O P E R A T IO N
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Figure 22. Results of radioactive iodine tests of thyroid function 
hefore and after successful treatment. In this figure solid 
circles represent the results when the patient was thyrotoxic, 
and open circles the results when euthyroid after treatment.
In most circumstances, therefore, this latter test
would appear to be preferable to any other as a diagnostic
index, but one inconsistency has been encountered which
renders it less valuable in certain cases.. The results of
the various tests are shown in Figure 22 when they have been
carried out in a group of patients before and after
successful treatment with either radioactive iodine, or by
partial thyroidectomy. Experience in this group of cases
has shown that 4 hour uptake figures and clearance rates have
of •
more accurately reflected the restoration/clinically normal 
thyroid function than have the 48 hour protein-bound plasma 
figures. It can be seen that the initially elevated uptake
f
figures and, with one exception, the clearance rates, all 
returned within or near the normal range, whereas although, 
there was usually a fall in the protein-bound plasma levels, 
it did not usually fall within the range, below 0.4% Ver litre, 
that is usually found to be associated with normal and non­
toxic thyroid function in the untreated case. In such cases 
there appears to be a delay in the return of protein-bound 
plasma activity levels to the normal, following successful 
treatment, and clinical cure precedes the objective evidence 
of normal thyroid function as shown by this test. Hall (1950) 
has demonstrated that in some cases of thyroid disease a 
significant amount of activity may be present in the 
diiodotyrosine fraction of the protein-bound iodine in the 
plasma, and that with the lapse of longer time intervals
between the administration of the radioactive iodine and the 
withdrawing of the blood sample, the greater is the proportion 
of the radioactivity present in the thyroxine fraction of the 
plasma. It is conceivable that in these treated cases this 
may be a partial explanation of the anomalous cases, and this 
can only be tested by checking the fractionaiibn of the samples 
by the method of Taurog and Chaikoff (1948). It is more 
probable, howevern that the phenomenon is related to an 
alteration in the specific activity of the labelled thyroxine 
following treatment, only a small amount of functioning thyroid 
tissue being left, and it is being forced to synthesize 
thyroxine at a high rate. This hypothesis can only be tested 
by extensive parallel studies of radioactivity levels in 
plasma samples whose chemical protein-bound iodine content is 
being simultaneously estimated.
The findings, however, indicate that as a diagnostic 
index, 48-hour protein-bound plasma activity figures are less 
valuable if the patient has had previous treatment by operation 
or with radioactive iodine, but for how long this Bnbffialy - 
persists, there is as yet no indication.
Nevertheless, it is my considered opinion that if one 
single and easily performed test of thyroid function is 
required, then the estimation of the protein-bound plasma 
activity 48 hours after the administration of radioactive 
iodine gives the most valuable diagnostic information, and 
this test is suitable as a screening procedure on outpatients.
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It should be realised, however, that no routine test 
of a single thyroid function is, by itself, adequate to 
establish the existence of abnormal thyroid activity, and 
radioactive iodine tests should be regarded as supplementary 
to other tests. Werner, Hamilton, Leifer, and Goodwin, (1950) 
claim that the combined use of gland uptake of radioactive 
iodine, basal metabolic rate determination, and chemical 
estimation of protein-bound iodine leads to 95$ accuracy in 
the assessment of overall thyroid function. Similarly, with 
regard to the use of radioactive iodine, we have felt that 
if one is going to obtain and use the equipment necessary, it 
is worth while investigating every patient as fully as possible, 
so as to gain a composite picture of different aspects of 
thyroid function. From such a study the most accurate 
deductions can be drawn regarding the degree of over or 
underactivity of the gland.
The primary aim of this investigation was to deftos ^ 
the best objective tests which would indicate the presence of 
thyrotoxicosis. There was not made, therefore, a detailed' 
attempt to differentiate between the mechanism of primary 
thyrotoxicosis, and thyrotoxicosis secondary to previously 
existing adenomata or nodular goitres. The two groups are 
roughly separated in Appendix Iir and IV and the means of the 
results of the investigations in these two groups have been 
separately presented in Table I- .. The metabolism of radioactive 
iodine appears to be very similar in both groups, but we have
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no evidence that it is identical.
Results of tests of thyroid function using radioactive 
iodine should always be regarded as supplementary and not 
replacing any of the other information available to the 
physician. The final decision must always be taken with 
all the information available from all sources, to be 
co-ordinated by the physician to the best of his ability and
in the light of his experience.
There will always remain patients about whose 
thyroid function the clinician remains in doubt even after 
the fullest clinical and laboratory investigation. If 
their iodine metabolism is investigated by the isotope 
technique valuable additional information is obtained and it 
is felt that great reliance can be placed on these results.
The accuracy of the final diagnosis with its therapeutic
and prognostic implications is thereby greatly enhanced.
2• The Diagnosis of Thyrotoxicosis Factitia
The fact that, as has been shown above, true? 
thyrotoxicosis is associated with an increased gland uptake 
of iodine renders possible the deLection of thyrotoxicosis 
due to the ingastion, usually overtly, of thyroid extract.
Such patients, some of whom have been described by Skanse 
and Riggs (1948) show the clinical features of thyrotoxicosis, 
an elevated basal metabolic rate, and, in contrast to true 
thyrotoxicosis, very low or negligible uptake of the isotope 
into the gland, the greater part of the tracer dose being 
excreted in the urine. This finding reflects the depression
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of endogenous thyroxine production by the ingested extract.
3e The Diagnosis of Myxoedema
On the basis of the cases studied in Part A of the 
study of the techniques applicable to the diagnosis of thyro­
toxicosis, it can be seen in Figures 6 and 7 that myxoedema is 
probably more accurately diagnosed by in vivo measurements of 
gland uptake than by 24 hour urinary excretion, clearance rates, 
or plasma activity levels. Nevertheless, from the practical 
point of view, as there is a delay in the excretion of the 
isotope, probably the most useful supportive test for the 
diagnosis of hypothyroidism is the raised urinary excretion of 
the isotope in the 24-48 hour period, as shown by Skanse (1949) 
and Arnott, Emery,Fraser and Hobson (1949).
Primary and secondary myxoedema can be differentiated 
by the radioactive iodine technique, as an initial low uptake 
of the isotope can be raised following the injection of 
thyrotopic hormone, if the myxoedema is secondary to a pituitary 
deficiency. This does not occur in primary myxoedema.
(Stanley and Astwood,1949); Reiss, Hemphill,Murphy,Halkerston 
and Badrick,1949). I have no experience of the use of this 
particular application of radioactive iodine.
4i_ Diagnosis of Retrosternal Goitre
Not infrequently the presence of a retrosternal thyroid 
gland, or retrosternal extension from a normal thyroid gland, 
be suspected as the cause of obstructive symptons of 
various degrees of severity. Occasionally also, thyrotoxicosis
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may be found with little or absent glandular enlargement, and 
in some of these cases the overfunctioning gland may be 
situated retrosternally• Such cases can easily be demonstrated, 
as has been done by Ansell and Rotblat (1948), by the localisation 
with a collimated Geiger counter of the site where administered 
raaioactive iodine is concentrated. 3y a similar technique it 
is possiole to exc-ude, or confirm, an intrathoracic thyroid 
as the cause of an obscure mediastinal tumour detected either 
clinically or radiologically.
Our experience is that the technique is easily 
applicable, and when the necessary equipment is already available, 
it is very well worth while administering a tracer dose of the 
isotope to any patient in whom there is doubt regarding the 
nature of a radiological shadow in the thoracic inlet, or 
the cause of unexplained mediastinal obstruction. In no case, 
however, have we found an unsuspected goitre retrosternally, 
although clinical and radiological evidence of goitre has been 
confirmed on several occasions. In numerous Instances the 
technique has- been used to exclude functioning thyroid tissue 
as the cause of a suspected obstruction. It should.always be 
remembered that the great majority of cancers of the thyroid 
do not concentrate iodine, and a negative result to a 
retrosternal "search” for concentrated radioactive iodine does 
not rule out the possibility of malignancy in an intrathoracic 
goitre, with replacement by tumour of all the normal thyroid
tissue.
The Diagnosis of Benign.. Tumours of the Thyroid
The localisation of radioactive iodine in thyroid 
tissue makes it possiole to determine whether or not a tumour 
in the thyroid is concentrating more, or less, iodine than the 
surrounding thyroid tissue. This can be done by directional 
counting with a Geiger counter so as to be able to find the 
relative concentration of the isotope ^n the tumour, as 
described by Dobyns, Skanse and Maloof (1948) who have shown 
that some tumours concentrate more, and some less iodine.
Means (1949) has aptly described these as "hot” or "cold" 
modules respectively, and the solitary toxic thyroid adenoma 
in a typical "hot" nodule. A modification of this method with 
a less well collimated counter, was used to show that cases 
87, 89 and 92 (in Part A of the Diagnosis* of Thyrotoxicosis 
section of this thesis,) had concentrations of the isotope in 
the adenomas several times greater than the concentration of the 
isotope in the surrounding gland.
Conversely, nodules in the thyroid which show less 
activity may be benign,non-functioning, ademonata or they may 
be malignant growths.. The demonstration by this technique 
of absence of iodine concentration at the site of an abnormal • 
thyroid swelling may be taken as supportive evidence that the
swelling is carcinomatous.
Alternatively,Jthe technique of autoradiography may 
be used to demonstrate the relative concentration of iodine in 
tumours and Cope, Rawson and McArthur (1947) and Dobyns and
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and Lennan (1948) have studied thyroid function by this 
technique. It, in principle, involves the radiation from 
the isotope being recorded on a photographic plate so that 
its presence can be detected in a histological preparation.
In essence, the usual histological sections are mounted on 
plates or slides coated with photographic emulsion which are 
then developed and fixed after exposure for several days, and 
finally stained. The anatomical structures of the section 
are then seen with superimposed upon the section the 
blackening due to the radiation from the contained radioactive 
iodine.
The ability of carcinomatous tissue to’ concentrate 
radioactive iodine can be assessed in this way from biopsy 
specimens, and the information used to guide treatment.
(See Section on Treatment of Carcimoffia of Thyroid)..
Diagnosis- of Carcinoma.
As just mentioned, the isotope can be used to detect 
increased or diminished iodine concentrating ability in a 
tumour and this can be of some value in the diagnosis of 
carcinoma of the thyroid.
Its real use, however, is made possible in those 
few cases, about 15 or 20% at most, of carcinomas that actually 
do concentrate iodine. Metastases of such growths may
not infrequently be detected, if appreciably distant from 
the site of the thyroid, by the gamma rays emitted from them.
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In this way functional boney*pulmonary,or glandular secondaries 
may be found. As will be described later, occasionally such 
a metastasis may be induced to concentrate iodine after 
removal of the primary growth and normal thryoid tissue, even 
although initially little iodine concentrating ability in the 
metastasis may be evident.
-86-
SECTION IV.
ram^EUTIC_APPLICATIOJ__OF RADIOACTIVE IODINE.
1 • The Treatment _of_Thyrotoxicosis
Princigles involved in__the_use of radioactive iodine
The treatment of thyrotoxicosis and toxic adenomata has 
traditionally been either by surgical excision of an arbitrary 
amount of the overactive gland, or alternatively, by the 
administration of suitable antithyroid agents, to prevent 
the synthesis of the thyroid hormone, the presence of which 
in excess quantities in the circulation is responsible for 
most of the symptoms of the disease.
Radiation by X-rays has been regarded as a satisfactory 
form of treatment by some people, but its chief disadvantage 
is that it is difficult to deliver an adequate dose to the 
gland without damaging the skin and causing severe mucosal 
reactions in the trachea and oesophagus. The biological 
effect on the tissues of the radiation from radioactive 
iodine is similar to that of X-rays; because, however, iodine 
is in general specifically concentrated in the thyroid gland, 
it is possible to deliver a very high local dose of radiation 
to functioning thyroid tissues with only a minimal effect on 
other organs in the body. The greater part of the therapeutic 
effect of radioactive iodine is provided by the beta radiation 
emitted by the isotope, and as this does not travel further 
than 2.2. millimetres in tissue, there is little effect on the 
organs beyond the capsule of the gland. Radioactive iodine is, 
therefore, a therapeutic weapon with which highly specific
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treatment can be given to one particular type of tissue - 
thyroid gland tissue; that concentrates iodine.
Practical App1ication
Radioactive iodine was first used in the treatment 
of thyrotoxicosis by Hertz and Roberts in 1942, and reports 
of its use have appeared from several American centres. 
Soley and Foreman (1949) have contributed a valuable 
review on the subject. More recently further series of 
American cases have been reported by Werner, Quimby and 
Schmidt (1949(b); Williams, Towery, Jaffe, Rogers and 
Tagnon (1949); Feitelberg, Kaunitz, Silver, Simon, 
Wasserman, and Yohalem (1950); Gordon and Albright (1950),
t
Moe, Adams, Rule, Moore, Kearns and Clark (1950); Shipley, 
Storaasli, ^riedell and Potts (1950); and McCullagh and 
Richards (1951).
Because, however, radioactive iodine did not 
become available for general clinical use in this country 
until very much later than in the United States, no reports 
of its application in the treatment of thyrotoxicosis are 
yet available from this country, and the series described 
here represents the first group of patients in Europe 
treated with the isotope.
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Selection of Cases
Opinion regarding the indications for radioactive 
iodine therapy has not yet crystallised and every group of 
workers in the field has come to its own conclusions regarding 
the policy to adopt. Chapman, Corner, Robinson and Evans 
(1948) found iodine concentrated in the human foetal thyroid 
about the fourteenth week of gestation and accordingly Chapman 
and Evans (1949) have stated that the only clear indication 
against the use of radioactive iodine for the treatment of 
thyrotoxicosis is in patients oejond the fourth month of 
pregnancy. Because, however, there is still not full knowledge 
regarding the late effects of internally administered 
radiation from radioactive isotopes, many groups are still 
restricting its use to certain categories of patients. Crile, 
McCullagh and Glasser (1949), have decided that it is the 
treatment of choice for those patients with thyrotoxicosis 
recurrent after operation, for those who are bad surgical risks 
and for elderly patients. Williams (1947) some years ago 
gave similar indications, and, in addition, included 
sensitivity to, refractoriness to, or lack of co-operation in 
the taking of antithyroid drugs such as the thiouracil group 
of compounds, and Werner, Goodwin, Quimby and Schmidt (1950) 
agree.
In general, current British opinion is to the effect that 
it is primarily indicated for recurrent tnyrotoxicosis, (Trotter, 
1950), and opinion regarding the other categories will form
\Table IV 
Summary of previous treatment 
given to cases of •thyrotoxicosis treated with 
radioactive iodine.
Ko. of Cases
Recurrent thyrotoxicosis S
after operation.
Patients who had had reactions 
to, or failed to maintain a 
remission following, the use 
of methyl thiouracil:
where operation contraindicated, 6
where operation refused, 3
where operation not offered, 5 ^4
Patients given radioactive iodine as
the treatment of election: £>
Total cases treated 30
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as experience accumulated in this country.
The principle adopted in the selection of patients 
discussed in this series has been that radioactive iodine therapy 
has been suitable for patients in the older age groups, unless 
with large or unsightly goitres causing tracheal pressure or 
deviation, but that in certain circumstances it may be the most 
suitable form of therapy whatever the age of the patient.
The first patient was treated on 12th January, 194$, 
and up to 31st July, 1951, a total of 49 patients received 
radioactive iodine therapy for thyrotoxicosis and 30 of these 
have been observed following treatment for 3 months or longer; 
these cases only will be discussed and the results analysed.
Full details of all cases are given in Appendix Vlll, 
and for the purpose of this section of the thesis, the cases 
are renumbered, with cross reference to their numbering in the 
diagnostic section.
The cases can conveniently be grouped into categories 
regarding their selection for treatment, and these are 
summarised in Table IV. It can be seen from this table and 
from Appendix Vlll that there had been a failure of other 
methods of treatment in all cases except in the eight patients 
in whom it was the treatment of election. These 8 were all
over 45 years of age except one male and one girl of 22.
f
She had severe exphthalmos and was unsuitable for operation,
and it was not felt justifiable to treat her with methyl
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thiouracil* as she lived a very long way from hospital and 
was unable to attend for frequent supervision of therapy.
The series consists of 24 women and 6 men, the average 
age of both sexes being 48, but the range of ages was 20 to 
73 years. Twenty five of the patients were classified as 
having diffuse and five as having nodular goitres.
Technique Used
All cases treated were studied as in-patients and all 
investigations were carried out in the medical wards and 
adjoining laboratories. 'Ahen the patients had been fully 
assessed, and preliminary tracer investigations completed, they 
were transferred for their therapeutic dose of radioactive iodine 
to the Radiotherapy Wards of the Infirmary. This was done to 
isolate patients receiving large doses of radioactive from 
otheig receiving tracer doses and in order to minimise the 
possibility of contamination of samples obtained from patients.
The solutions of radioactive iodine used, being of very 
much higher activity, 500 to 1000 times as much, as those used 
in tracer tests, were handled with especial care and precautions; 
dispensing of the required dose from the solution as received from 
Harwell was done by remote control methods.
The patients drank the radioactive iodine solution 
through a bent glass tube and all patients were rehearsed in 
this technique using water before being given the active solution.
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All urine from patients undergoing therapy was stored 
in cylindrical cans whose simple geometric shape made possible 
the estimation of urinary volumes without further handling. 
Faeces were not normally kept unless contaminated with urine 
but were put down the sluice with repeated flushings. Urine 
was normally kept in any one container until the activity had 
decayed to below 1 millicurie. Carrier sodium iodide was 
added before it was put into the sluice emptying into the 
main hospital drain. Not more than one millicurie was so 
discarded per week.
The patient undergoing therapy was kept isolated in a 
separate ward. Crockery, bed pans, etc., were used only In 
that ward and were checked for contamination at the end of the 
treatment. Urine, and blood were taken ’wearing rubber gloves 
and gowns. All bed linen and towels were checked for 
contamination after the patient had been discharged and any 
article which showed appreciable activity was washed in a 
machine by itself.
After discharge from hospital, usually about a week or 
ten days after the therapeutic drink, patients were seen one 
week later at the Outpatient Endocrine Clinic, and thereafter 
they were seen at two or three week intervals until they 
became clinically euthyroid. Thereafter they were seen at
increasing intervals, and all are currently under observation.
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Dosage
The problem of the selection of the correct number 
of millicuries in the drink of the isotope to be given to each 
patient is of fundamental importance and is dependent on 
several factors, reviev/ed by Williams, Jaffe, Towery, Rogers 
and Tagnon (1949). Most American groups have aimed at 
giving a drink containing about 100-200 pcs. per gram of 
estimated thyroid mass. It has been felt in Sheffield, 
however, that, insofar as it is practical and possible, a 
careful attempt should be made to predict and administer, a 
drink for each patient which will result in a dosage in 
"equivalent roentgens" (e.r) (being the total of beta and 
gamma ray dosage) to the thyroid gland of between bOOO to 
10,000 er.
The roentgen dosage following a drink containing a 
specified numb®1 of millicuries is dependent on three variables, 
characteristic of the patient at the time of therapy, not ail 
of which can be accurately predetermined. These are (a) the 
fraction of the total active iodine administered, taken up in 
the gland (b) the rate of elimination of the iodine from the 
thyroid and (c) the total mass of the gland. The first two 
of these can be determined by a preliminary tracer 
investigation and this must be done on all patients for whom 
therapeutic doses are ' contemplated. Until recently we 
have only been able to determine the mass of the gland by 
palpation, and this can be no more than an intelligent guess.
In the series to be described palpation estimates have been
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used in dosage assessments, but a technique has now been devised 
by Mr. J.C.Jones, Assistant Physicist at the Sheffield National 
Centre for Radiotherapy whereby it is possible to obtain a more 
accurate and objective estimate of gland size by the use of a 
collimated G-eiger counter.
The formula tnat has been used in calculating dosage is:
Dose (D) = (210 1" 10) v T.U.M. equivalent
W
Roentgens, (e.r.) where 
T is the total (not biological) half life, i.e. the 
time taken for the actual measured radioactive content of the 
gland .to fall to half its initial peak value, (days)., U. is 
the peak value of the percentage of the administered iodine 
taken up by the thyroid; and W is the mass of the thyroid in 
grams, estimated clinically by palpation.
This dosage includes the contribution of both beta and 
gamma rays, the beta ray dose being independent of the shape of, 
that gland, which does affect the gamma ray dose, but in any 
case the latter component is only some 10% of the total dose.
The factor (210 jr 10) has been calculated from the average 
beta ray energy and that of the gamma rayfeh emitted, using 
suitable data provided for the purpose by the Atomic Energy 
Research Establishment, Harwell.
G-enerally speaking, the tracer measurements of peak 
uptake and of half-life are fairly well reproduced by the 
therapeutic drink, and the predicted dose actually delivered 
to the gland. Table V shows, in the first 20 cases of this
Table V
Comparison of results obtained from 
measurements following tracer and therapeutic 
drinks of radioactive iodine.
Dose (e.r.)
Case Peak Total ^ life Predicted Calculated
No. uptake, $ (days) from from
Tracer Therapy Tracer Therapy Tracer Therapy
1 22 72 - 5.2 - 12,000
2 75 77 5.4 6.1 8,700 9,900
3 72 73 3.1 20 after 
2 days.
6,750 10,550
4 75 16 3.1 3.7 7,100 1,800
5 75 69 l.6o 1.43 2,400 1,930
6 60 6o 6.4 4.0 11,000 6,900
7 6 l 6o 3.0 3.1 7,500 7,700
s 71 70 - 6.2 - 15,700
9 77 36 3.7 3.1 10,200 9,500
10 76 25 3.1 2.8 & . 
5.4
7,000 10,600
11 62 56 5.0 5.2 6,700 6,600
12 27 93 3.7 3.4 
after 1 day
11,700 8,200
13 6i 54 4.9 2.6 & 
6.8
7,200 7,400
!4 92 27 2.6 ,1.79 & 
3.32
7,000 6,200
15 72 27 3.2 5.9 8,000 13,600
16 25 79 3.9 4.2 9,500 11,000
17 75 92 3.1 2.3 & 
3.7
10,000 12,700
13 11 24 5.0 4.5 T O T T  - 9»/00"
19 25 27 4.5 5.4 10,500 12,700
20 27 77 4 5.4 5,000 5,600
-94-
series, how thes© two factors varied on the two occasions*
It can De seen that the total half life shows greater 
divergence in the therapeutic drink fromthat predicted for 
the tracer dose, than did the peak uptake. Doses calculated 
retrospectively from data derived from measurements following 
therapy are seen to correspond fairly well with the expected 
dose, and variations are chiefly due to variations in the 
total half life. This appears to be an unpredictable 
biological effect which must be taken into consideration when 
prescribing the dose for the patient. In case 5 the tracer 
total half life was only 1.6 days, and this meant that, to 
deliver an adequate roentgen dosage to the gland a high 
millicurie dosage was necessary. If following the therapy 
drink the isotope had had a larger total half life than 
expected, over-irradiation of the gland would have occurred. 
Accordingly, therefore, an intentionally small dose was 
prescribed, in her case, but in the event the total half life 
of the therapy drink was shorter than expected, and the dosage 
delivered therefore quite inadequate; a second.drink was later 
given.
Nevertheless, despite occasional variances, dosage can 
be rendered more precise if preliminary note is made of the 
half life, as of the uptake, in the tracer investigation.
The greatest error in dosage prediction is likely to be 
introduced by estimations of gland size. Williams, Jaffe, 
Towery, Rogers and Tagnojn (1949) and Wwrner, Quimby and Schmidt 
(1949), found close agreement with practice between estimated
Figure 2 Equipnent used to determine the distribution of radioactive 
iodine in the thyroid gland, using a collimated G-eiger counter.
I
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and actual gland size as found after operation, the srror with 
the latter workers being 30%. I have not an extensive 
comparative series to check on clinical estimates of gland 
mass but it is felt that the inaccuracies of the method are 
not such as to affect seriously the estimations of the dose 
given.
In order to check this and to provide an independent 
and probably more accurate method of estimation, an attempt 
has been made recently by Mr. J.G.Jones in Sheffield to develop 
a technique of estimating the gland volume by means of G-eiger 
counter measurements. The counting rate, produced in a 
highly collimated gamma counter (Veall, 1950) is recorded when 
this is moved from point to point in a plane over the gland.
This gives an estimate of the amount of active iodine within 
the field of the counter and if the concentration of the iodine 
is uniform, a figure proportional to the thickness of the 
gland in that direction.
The counting rate is measured with the counter axis 
perpendicular to both the coronal plan€ and the saggital plane 
at centimetre intervals. The arrangement for the coronal 
plane is shown in Figure 23- A bridge consisting of a 
perspex sheet on which a co-ordinate system is ruled, is placed 
over and as near as possible to the neck of the patient who 
lies on her back with neck extended. The counter, which stands 
on three snort legs, is moved from point to point in the plane.
Figure 24. Distribution of radioactive iodine in the thyroid gland 
three days after ingestion of a therapeutic dose. The contours 
are lines along which the counting rate per minute in a collimated 
Geiger counter was constant.
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For measurements with the counter axis perpendicular 
to the saggital plane the patient remains on her back and the 
counter is placed horizontally in a stand which can be raised 
by the insertion of wooden blocks and can be moved 
horizontally along a scale.
Diagrams are drawn showing lines of equal counting 
rate. A normally shaped thyroid produces diagrams similar 
to that shown in Figure 24. Anatolical features are noted 
on the co-ordinate system and transferred to the diagram as 
shown. Another diagram is drawn from the measurements made 
with the counter in the plane at right angles to the first. 
These diagrams shov/ the general shape of the gland but even 
an approximate estimation of the volume presents many 
difficulties and involves highly complex mathematical and 
physical computations which are beyond the scope of this 
thesis to discuss.
The technique has been carefully calibrated by 
measurements of the volume of models of known shape and volume 
when these models have been mounted in scattering material to 
stimulate the effect of the tissues surrounding the thyroid. 
The resulting diagram obtained in the coronal plane for a 
glass model thyroid is shown in Figure 25. In association 
with the corresponding diagram in the sagittal plane an 
estimate of the model’s volume was made of 51 ml., the true 
volume being 63 ml.
I OCXso;
Figure 25. Diagram of lines of equal counting rate over a 
radioactive glass model thyroid. Estimated volume, 51 
True volume, 63 ml.
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Sufficient be it to state that we believe that this 
technique, carefully and intelligently applied, will provide 
an accurate method of assessment of gland size, and thus 
define precisely trie third variable factor, the knowledge 
of which is necessary for accurate dosage measurement.
Table VI shows thfc§_results of the application of 
this new technique in ten recent cases, not included in the 
series here reviewed. The first two columns represent the 
predicted and actual dosages delivered to the glands, assuming 
the accuracy of palpation estimates of gland volume. In 
the last column the calculated volume is used following the 
measurements made after the therapeutic drink, and differences 
between the last 2 columns are due to differences between the 
estimates of gland size as measured by palpation and by the 
new technique.
So far it has not been possible to make such 
measurements on patients at the tracer stage flrith the present 
size of tracer drink (30 pcs) and volumes can, therefore, 
be estimated in this way only after therapy, unless a larger
tracer drink is given to assess gland size before the therapeutic 
drink. : It is, of course, perfectly justifiable to administer
to patients for whom therapy is intended tracer drinks of the 
order of 100 to 200 pcs. Development of the use of 
scintillation counting may render even this size of dose 
unnecessary in the future, as has recently been described 
by Allen, Libby and Cassen (1951).
Table 71
Comparison of,
Column A : Gland doses predicted from
tracer measurements, using the gland volume 
as estimated by palpation.
Column B : Gland doses as measured
following therapeutic drink, using gland volume 
as estimated by palpation.
Column C : Gland doses as measured following
therapeutic drink, but using gland volume as 
calculated from plot of curves of equal counting 
rate.
1 *. 0*.
1 S,000 s ,6oo 4,300
2 10,SOO 13,500 13,500
3 7,900 7,500 7,500
4 s,700 s,300 8,300
5 9,000 5,600 4,700
6 8,000 7,300 4,800
7 11,000 11,800 8,500
s 6,200 6,200 5,600
9 8,500 11,300 10,200
10 8,000 7,300 4,900
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In the calculations of the dose delivered, the further 
necessary assumption has to be made, that the absorbed iodine 
is distributed uniformly throughout the gland. Measurements 
described above with a collimated counter show that for most 
cases of thyrotoxicosis there is little or no gross heterogeneity. 
Autoradiographic studies have, however, shown heterogeneity 
larger- than the range of the beta particles, so that some cells 
will receive considerably more, and some considerably less, than 
the average amount of radiation.
An autoradiograph, illustrated in Figure 26, was made 
from a biopsy specimen taken from the gland of Case 3 twelve 
months after her second therapeutic drink of radioactive iodine, 
and following a further tracer dose of the isotope. It 
illustrates well the patchy distribution of the isotope in the 
gland, and also the fibrosis which has occurred in the gland 
following the previous treatment. There is no way of 
estimating such a variation in the distribution of the isotope 
in any particular patient, but it seems likely, however, that 
the areas which absorb most iodine, and, therefore, presumably 
those which are most actively producing thyroxine, are receiving 
doses considerably in excess of the average dose throughout the 
gland.
Finally, the last unknown and completely unpredictable 
factor is the undoubted variation from patient to patient of the 
sensitivity of the thyroid gland to radiation. It seems 
unlikely that any particular dose, whether stated in milliouries,
Figure 26. Autoradiographs of thyroid adenoma 1 year after treatment 
with radioactive iodine, and following a further tracer dose 
before biopsy. (Case 3.)
The section is counter stained with Masson’s light green 
trichrome. It shows the fibrosis often associated with thyroid 
adenoma, but in this case attributable in part to previous 
radioactive iodine therapy. Note the rather patchy distribution 
of the isotope, the highest concentration appearing in the more 
active follicles.
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or in equivalent roentgens to the gland,should prove exactly 
suitable for producing normal thyroid function in every patient 
without an occasional error in one direction or another.
The optimum dosage can only be decided by trial and error, in
the knowledge that underdosage is always preferable to over­
dosage, as failure to obtain a remission can always be
remedied by the administration of a further dose.
It is known that the thyroid gland is not particularly 
sensitive to radiation, as it is extremely difficult, apart 
from the complicating factors that ensue, to induce hypo- 
thyroidim by X-ray therapy^ and orthodox deep x-ray or radiugi 
therapy for hyperthyroidism was often carried out to the 
limits of skin or mucous membrane tolerance without success.
In rats no histological changes, nor reduction in function, 
are produced by local X-ray doses up to as high as 5,000 r. 
(Bender, 1948). Results in animals are, however, difficult 
to interpret, but the consensus of opinion would appear to be 
that in man a dosage of about 8,000 to 10,000 er. is probably 
about the suitable level at wnich to aim in the treatment 
of thyrotoxicosis, and this has been the dose wiiich in 
Sheffield we have attempted to deliver to the gland.
Results of Treatment
The clinical status at 31/7/51 of the patients 
in this group is shown in Table Vll. It can be seen that 
all patients who have been observed for more than ten months
Table VII 
Present clinical status of cases 
treated with radioactive iodine, related to 
duration of observation following the 
last dose of the isotope.
Period of 
observation 
(months)
Euthyroid
(no.
Hypothyroid 
of cases)
I«ffi£py.s4
(but
not
euthyroid)
3 - 1 0 7 - S
1 1 - 2 4 14 1 -
3 - 2 4 21 1 8
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are cured of hyperthyroidism, one patient only being 
hypothyroid. Of the patients observed for a shorter period, 
all have improved, some very considerably and seven of them 
also are euthyroid, but the remainder require a further dose 
to complete treatment and render them completely normal 
clinically. Treatment, cannot be regarded as being yet 
completed in those cases, for the eventual restoration of 
normal thyroid function can be anticipated in all cases 
treated, and this has been the experience also of Feitelberg, 
Kauritz, Silver, Simon, Wasserman, and Yohalem (1950), 
although in some cases multiple doses of the isotope may 
be required. ^
The relationship of the patients clinical status 
to the number of doses administered is shown in Table VIII.
The only patient who has received 3 doses is Case 3 who had, 
and still has, a large nodular goitre and she illustrates the 
fact, as shown by Richard, Crile and McCullagh (1950), that 
very much larger doses are required for toxic nodular goitre 
than for thyrotoxicosis with diffuse■gland enlargement.
The fact that 18 out of the 30 patients were cured with only 
a single dose is taken as evidence of the value of careful 
preliminary measurements for dosage assessment.
With regard to the gains in weight following treatment, 
the patients who improved, but were not rendered completely 
normal, gained an average of 10 lbs, whereas the group that
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became euthyroid gained an average of 19 lbs. The single
hypothyroid patient gained two stone (28 lbs) but some
members of the euthyroid group put on as much weight, and
one patient (Case 9) gained over 47 pounds in weight with
residual normal thyroid function. The change in the
appearance of this patient is well seen in Figure 27. (p,102)
There was a diminution in the size of the thyroid
gland in most cases, including Case 3, the case of toxic
nodular goitre with a very large gland. Small pseudo-
adenomatous nodules associated with recurrences after
thyroidectomy practicaxly disappeared. The diminution of
the gland size, and improvement in the patientfs facial
appearance and demeanour, is evident in Figure 28. (p.104)
It was noted that clinical improvement with remission
and disappearance of the clinical signs and symptons of the
disease was not apparent for between 3 to 6 weeks, a time
which corresponds with the experience of Hursh and Karr (1951).
The time that elapses until the clinical response is evident
depends to a certain extent on the pre-existing level of
toxicity, but an early clinical improvement may herald eventual
evidence of temporary or permanent hypothyroidism due to
131
overtreatment. . Using this isotope of iodine, 1 , it takes
more than 20 days to have 90% of the radiation delivered, and
this partly accounts for the delayed response. If there is
no improvement within 8 weeks, the initial dose can be 
considered to have been inadequate and a further drink is
Figure 27 (a). FactS of patient (Case 9) before, (23.12.49), and 
after, (S. 12.50) treatment with radioactive iodine.
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indicated. This usually happens in those cases where the 
calculated initial roentgen dose to the gland is too low 
(Cases 4, 5 and 20) but knowledge of the delivered roentgen 
dosage is not a reliable guide to the clinical response.
Figure 29 shows the effect of the initial dose in this series, 
the dose to the gland being calculated retrospectively from 
the actual uptake of the isotope into the gland, and its 
biological half-life, the volume of the gland being estimated 
clinically by palpation, (p.107).
It can be seen, as would be expected, that there is 
no relationship between the actual total number of millicuries 
of radioiodine in the drink, and^the effectiveness of the 
dose.
All the 18 patients who became euthyroid after a 
single treatment, received more than 6,000 e.r., the average 
dose being 9,5000 e.r. Those patients in whom the response 
was inadequate usually received a dose well below this level, 
either because the uptake of the therapeutic dose was smaller, 
or its biological half-life shorter, than anticipated. The 
average dose in those who failed to respond sufficiently to 
the first dose was approximately 8,000 e.r. The patients 
who required more than one treatment to become euthyroid 
received, a total average summated dose of 15,000 e.r.
't
v
-
Figure 27 (t>) • Face and trunk of same patient, (Case 9) "before and 
after treatment with radioactive iodine. V/eight gain: 47 lbs.
Residual normal thyroid function, (see text.)
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i
A number of the patients successfully treated have had 
repeat tests of their thyroid function carried out with radioactive 
iodine, and these results have already been presented and 
discussed in Figure 22, in SectionlH Part B.
Complications
In no case was there any local reaction to the therapy, 
and there was no hoarseness, laryngitis nor salivary gland 
reaction in any patient treated in this series, although a 
few had transient tenderness of the gland for a few days about 
a fortnight after treatment. Nor was there any general 
systemic reaction, although nausea and occasional sickness may 
occur following very large doses of 100 millicuries or more used 
for treatment of malignant disease of the thyroid.
In no case in this series was there any temporary 
exacerbation of thyrotoxicosis reported in a few cases by 
Williams, Towery, Jaffe, Rogers and Tagnon (1949) and mentioned 
by other groups. It has, however, been observed in one of 
the cases more recently treated, but responded satisfactorily 
to routine medical measures Including the administration of 
inorganic iodide. In 3 of the cases of this series, Cases 
10 (second dose) 14 and 29, the degree of thyrotoxicosis was 
very considerable, and a course of methyl thiouracil was given 
for a period of 4 weeks prior to the administration of the 
therapeutic dose of radioactive iodine. In these cases the
Figure 28 (a). Fu 11 face view of Case 10 before, (5.1.50), and after, 
(21.7.51) treatment with radioactive iodine.
Note disappearance of "stare” and anxious expression, and 
diminution in gland size. c.f. Fig. 28 (b) .
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antithyroid drug was withdrawn at least a week before a further
tracer dose of radioactive iodine, and it was found that gland
absorption had reverted to its previous level, as shown also by
Chapman and Evans (1949). The patients were, however, very
greatly clinically improved and it is felt that this procedure 
/
may reduce the risk of a transient exacerbation of thyrotoxicosis 
following the therapeutic dose.
Alternatively, it is possible and justifiable to 
administer small doses of potassium iodide, beginning not earlier 
than 24 hours after the therapeutic drink, to patients with 
severe toxicity. This gives the patient the benefit of the 
well known therapeutic action of iodides on thyrotoxicosis,
1
whereas there is no appreciable effect on the discharge from
the gland of the previously administered radioactive iodine,
which by that time is practically 100$ in protein-bound form.
This is now a routine practice in Sheffield with the more
%
severely ill patients.
Hypothyroidftn was, unfortunately, induced in one patient, 
Case 5. She had severe recurrent thyrotoxicosis, and was 
insufficiently controlled by her first therapeutic drink. The
second, however'# resulted in slight overtreatment with the 
gradual onset of many symptons of hypothyroidjfin and with an 
associated rise in her blood cholesteral from 205 to
340 mg.$ and she now receives maintenance dosgs of thyroxine.
Full face view of Case 10 before treatment
would not permit photograph, to be taken with her chest bared unless
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Transient hypothyroidism has occurred in two cases, 
Gases 4 and 9. In case 4, in which there was evidence of 
malignant , there was before treatment severe
thyrotoxicosis, with considerable wasting. Her first dose 
was considered to have been inadequate, and a few weeks 
after her second dose some degree of hypothyroidism 
developed without any deterioration in the eye signs, and 
treatment with thyroxine was instituted and has been 
maintained. On withdrawal of the drug, there was little 
alteration in her clinical picture, and gland uptake of 
radioactive iodine was of the order of 26$; thyroxine 
treatment was, however, given in an attempt to improve 
her exophthalmos by inhibition of pituitary thyrotropic 
hormone.
Case 9 was of special interest inasmuch as there was 
strong evidence of relative suprarenal cortical deficiency 
at the time when the patient was grossly thyrotoxic. 
Following his therapeutic dose of radioactive iodine, a 
very considerable gain in weight occurred (Figure 27), which 
was at one stage accompanied by evidence of hypothyroidism. 
Later, however, he was considered on clinical grounds to 
be in normal thyroid balance, and gland uptake of radio­
active iodine was fund to be 20$, in the low normal range. 
Arthritis. One patient, Case 19, had a severe attack of 
gout affecting one hand, beginning about one week after her 
therapeutic dose. This attack was possibly unassociated
Figure 28 (c) . Lateral view of face and neck of Case 10 before and 
after treatment, Note marked shrinkage of gland,
(N.B. These photographs are typical of other similar records.)
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with the administration of radioactive iodine, although it 
is known that a sudden metabolic disturbance, such as can 
be assumed to occur in the treatment of severe thyrotoxicosis 
with radioactive iodine, may sometimes fire off an attack in 
this condition. A further patient, Case 17, had an attack 
of arthritis, •characterised by painful swelling of his wrist 
and finger joints and associated with limitation of movement 
and tenderness of the extensor . tendons of his wrist, which 
occurred four months after his therapeutic dose. The condition, 
the precise etiology of which is not known, was treated with 
high dosage of calcium aspirin, and gradually returned to 
normal with no residual disability. Case 16, who had 
evidence of old rheumatoid arthritis of her hands, stated that 
she had a slight increase in the usual amount of pain and 
stiffness of her fingers in the few weeks following her 
treatment, but there was no objective alteration in her 
arthritic condition.
The relationship of the manifestations of joint 
disease in these patients to their thyrotoxic condition, or 
to the treatment given, is not clear, but is being at present
further studied.
C&r&estive heart failure had been a recurrent feature 
in Case 3, and occurred once again a few months after her 
second dose of radioactive iodine, and again a year later, 
when she• was once again thyrotoxic. She had a large nod.ular 
goitre and she received, as already mentioned, the highest
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Figure 29. Distribution of doses received in those cases cured with 
a single therapeutic drink of radioactive iodine, and in those 
who subsequently required further treatment.
total dosage given. There has been no further recurrence 
of congestive failure since her third therapeutic drink*
No detrimental effect of therapy was noted on the 
haemopoietic system, nor on any other organs. Following 
upon very high dosage of radioactive iodine given to a 
further case of metastatic thyroid carcinoma, I have observed 
a fall in blood platelets and a transient fall in the leukocyte 
and lymphccyt-e count, but there has been no similar effect in 
any case treated for thyrotoxicosis. One patient, in fact, 
(Case 19) had purpura with thrombocytopenia, there being only 
90,000 platelets per cu.mm. before treatment, a condition 
ascribed to her thyrotoxicosis. Following her therapeutic 
dose of radioactive iodine, her platelets steadily rose to a 
level of 330,000 per cu.mm. six weeks later.
No alteration in menstrual function has occurred, nor 
was there any alteration in the menses of a young patient 
successfully treated with several very large doses of 
radioactive iodine for recurrent thyroid carc^ iacteia, as will 
be described later.
Discussion of role of radioactive iodine in the therapy of 
of Thyrotoxicosis.
In a disease such as thyrotoxicosis where there are 
already available satisfactory, efficient, and relatively safe 
methods of treatment, the acceptance of a new form of therapy 
must be shown to have very considerable advantages before it 
can be universally adopted.
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. Medical treatment with one of the thiouracil 
derivatives is a suitable form of therapy for practically 
all cases of thyrotoxicosis except those with pronounced 
tracheal compression or deviation, or in cases where 
supervision of medical treatment is difficult. Treatment 
with methyl thiouracil results in a permanent remission of 
the disease, after withdrawal of the drug, in only about 
two-thirds of patients, even when treated for over a year. 
This relapse rate is very much higher if treatment is 
discontinued before 12 months; Dunlop and Rolland (1950) 
found that of 72 patients treated for up to 12 months,
50 relapsed, whereas of 54 cases treated for over 12 months, 
only lb subsequently relapsed. The great majority of 
relapses following methyl thiouracil therapy occur within 
4 months of withdrawing treatment, and Trotter (1950) showed 
that relapse is very rare after 30 months from the end of 
treatment. Iversen (1951) in a considerable series has 
reported relapse or true recurrence of symptoms in 44% of 
cases treated.
The real value of the drug is that with it patients 
may be tided over until natural remission of the disease 
occurs, natural remission occurring in about 50% of cases 
even if no effective treatment is given (Albutt, 1897)•
Its use is associated with a very small mortality, less than 
0.5%', and this is entirely due to agranulocytosis (Himsworth, 
1948). The incidence of this complication is now very much
smaller than it was soon after the introduction of the drug, 
as at that time very much higher dosage schedules were used.
About 10% of cases have toxic reactions to the drug 
which- Dunlop and Rolland (1950) found were sufficient to 
necessitate stopping treatment in 7%, but Iverson (1951) 
found he had to withdraw the drug in 14% of his patients 
because of adverse reactions. Such cases can usually be 
satisfactorily treated by operation. A major inconvenience 
of methylthiouracil therapy is undoubtedly the necessity 
for prolonged hospital attendance to control its use, and 
this has very definite psychological and physical disadvantages.
Thryotoxicosis should be -created surgically by 
choice where the gland is very large, or where there are 
pressure effects, and the resultant cosmetic effect is 
usually good. Surgery has the advantage that cure is more 
rapid, and more frequently permanent, than in cases treated 
solely with methyl thiouracil. The chief disadvantage^f 
surgical treatment are that in this country, except in 
special clinics, the overall mortality rate is certainly 
considerably greater than 2% (Himsworth, 1948) and the 
majority of partial thyroidectomies are not carried out by 
specialists in the operation. There is moreover, an 
additional appreciable morbidity rate resulting from the 
operation or complications therefrom, and the patient is 
left with a scar which may be, especially in young women, 
a disfigurement.
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The great advantage of radioactive iodine is that 
there is no immediate risk of mortality nor morbidity, and 
the treatment, from the patient's point of view, is 
completely devoid of unpleasantness, and ...Supremely simple. 
There is remission of symptoms associated with shrinkage of 
the gland without any necessity for either prolonged hospital 
treatment an attendance or for a scar producing operation. 
Repeated small doses of radioactive iodine, given without 
detailed study, will result eventually in full remission in 
practically all cases, and this is the practice in many 
American clinics where no specific attempt is made to measure 
accurately the dose given to each patient. Such advantages 
as these must be balanced against any possible adverse effect 
that may result from the rad ioactivej^admini stored. The chief 
arguments against its more general application centre upon the 
possibility that malignant changes may be induced in the thyroid 
gland many years later. It is, however, significant that 
the oype of radiation known to be associated with the later 
development of malignant change is chronic radiation of low 
intensity, and not the brief and much more intense radiation 
provided by radioactive iodine (Werner, Quimby and Schmidt,
1949 (b)). Moreover, malignant change has not been noticed in 
the gland following external radition oy X-rays and Quimby and 
Werner (1949) reported the results of an enquiry among 
radiotherapists and thyroid specialistS of the late effects 
on cases treated by X-ray therapy for thyrotoxicosis.
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A1though malignant disease arose in some cases where 
the skin had been over-irradiated and in some cases in the 
trachea and the oesophagus, there was no evidence of malignancy 
arising in the gland as a result of ionising radiation.
Their conclusion was that this complication (malignant change 
in the gland) if it exists, must be very rare. Although the 
beta radiation of radioactive iodine is not strictly the same 
as the radiation of radium and deep X-ray therapy applied 
externally there is no reason to suppose that it is 
fundamentally different in its effects, apart from the fact 
that such radiation is localised to the gland itself and is 
more intense in places where the concentration may be patchy.
On a time scale basis, however, the radiation from 
radioactive iodine would appear to be intermediate in its 
effect between a chronic radiation of low intensity and the 
brief but intense radiation of X-rays.
Gorbman (1950) has carried out some experimental work 
on mice to which he gave very high dosages of radioactive 
iodine and determined the dosage level, in microcuries per 
milligram of thyroid tissue, necessary to extirpate thyroid 
cells completely. He studied the histological features of the 
thyroid glands which had been given doses insufficient to 
kill all the cells, and in no case was neoplastic growth, or 
even metaplastic replacement, observed in mice studied up to 
one and a half years after tne administration of tne 
radioiodine. He found, however, bhat the functional
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capacity of these surviving cells was impaired.
Doniach (1950) found that radioactive iodine 
significantly increased the formation of thyroid adenomas in 
rats as compared with controls not treated with radioactive 
iodine, in the following groups: those treated with radio­
active iodine alone, those treated with methyl thiouracil, o.ruL 
those treated with methyl thiouracil and acetylamino fluorene.
In addition,he found a thyroid cancer in the group of rats 
treated with radioactive iodine and methyl thiouracil, and 
one in the group treated with radioactive iodine, methyl 
thiouracil, and acetylaminofluorene. Doniach concludes from 
these findings that radioactive iodine acts indirectly as a 
stimulant of the production of pituitary thyrotropic hormone - 
increased production of which occurs after any treatment of 
thyrotoxicosis whether by surgery, thiouracil, or radioactive 
iodine - and acts directly as a carcinogen. He states that 
the effects vary in the gland according to the state of the 
cells and the dose received.
This work must (re interpreted with caution in view 
of the relatively small number of animals used, the high incidence 
of adenoma formation in the controls that did not receive 
radioactive iodine, and because increased adenoma formation, 
with occasionally apparently malignant changes, have been 
reported in rat§ by Griesbach, Kennedy, and Purves, (1945),
Purves and Griesbach (1946) and Gorbman (1947), following the 
chronic administration of goitrogens such as thiouracil. 
Bielschowsky (1945) has shown that acetylaminofluorene enhances
the effects of these agents. Furthermore, Gorbman (1947) 
showed that the apparently malignant infiltrating thyroid 
tissue disappeared and the supposedly cancerous glands 
involuted, on resumption of a normal diet.
Additionally, oecause of the minute size of the 
thyroid gland in rats and mice, experimental radiation effects 
are found in contiguous structures such as the trachea, which 
are within the range, 22 mm., of the beta radiation of 
radioactive iodine. In man, however, the thickness of the 
gland capsule and the presence of surrounding connective tissue 
makes such effects improbable, and Soley and Foreman (1949) 
point out that if a direct comparison could be made between 
results in animals and in man, from 210 to 3,500 millicuries 
would be required to produce total thyroid destruction in an 
adult of' 70 Kg. weight. This is very considerably more than 
is known to be required, and iS approximately 20 to 200 times 
the usual maximum order of dosage used in the treatment of 
thyrotoxicosis. This safety factor, derived from animal 
experimentation, is far greater than is usual with most 
therapeutic agents.
These findings chiefly serve to emphasise the 
difficulty inherent In the interpretation of histological 
findings relating to the thyroid gland. It is important to 
emphasise that there has not yet been produced any experimental 
or clinical evidence of the induction of carcinoma following 
the administration of radioactive iodine alone. It will be 
many years, of course, before such cases will appear, but, on
Table IX
Case
I&.
5
6
7
9
10
Summary of plasma and urine 
doses delivered following therapeutic drink 
of radioactive iodine for thyrotoxicosis.
Dose per 
mi Hi curie 
(e.r.)
Plasma Urine
u.o 3.0
1.3 2.7
2.8 2.3
3.6 1.8
2.3 1.0
Estimated dose 
actually given in 
treatment 
(e.r.)
UrinePlasma
77 
7
16
IS
<29
(46
22
15
14
9
(12
(20
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balance, all evidence goes to show that the possibility of 
such appearances is most remote. 1
With regard to adverse effects of other types, the 
possibility of irreversible changes occurring, especially in 
the gonads, must be considered. Because of the high 
concentration of the isotope in the gland, there is little 
irradiation to other body organs, and Gorbman (1950) considers 
that ovarian sterilisation by radioactive iodine need only be 
considered as a potential hazard when circumstances are such 
that thyroid iodine uptake is less than 10$.
In cases of thyrotoxicosis, in contrast to cases
the
of malignancy, a high proportion of/general rad.iatipn to organs 
other than the thyroid is due to the high level of circulating 
radioactive thyroxine, and in the treatment of thyrotoxicosis 
the actual ovarian dose is of the same order as the blood dose. 
The sterilising dose to the ovary is of the order of 250-400 r, 
and the possible genetic effects of such a dose are analogous 
to the effects resulting from diagnostic radiological 
investigations for gynaecological conditions and for pelvic 
mensuration.
Table IX lists a number of calculated blood plasma 
and urine doses which were estimated by integrating the plasma 
concentration with time. They were calculated from the tracer 
dose measurements o,f plasma radioactivity and refer to beta 
dose only, the gamma ray dose not being likely to contribute 
more than 20% of this dose. Myant (1951) has suggested that 
the circulating levels of radioactive thyroxine may be lower
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following the therapeutic drink than following the tracer 
measurements in which case these calculated doses would be 
too high.
The dose received by the cells is not likely to be 
appreciably greater than the plasma dose, and in most cases 
will be very much less, unless there is appreciable concentration 
of iodine in any other part of the body. The dose to the 
bladder walls will be between one half and one times the urine 
dose depending on the involution of the bladder surface.
Nevertheless, in one case, Case 5, the calculated 
plasma dose was quite considerable, and this was due to the 
fact that the patient had a very high degree of plasma 
radioactivity due to rapid gland turnover and conversion of 
the radioactive iodine into thyroxine. Repeated blood counts 
on this patient, followed over many months, have not revealed 
any abnormility in any constituent, nor, with the exception 
already mentioned in one case, have we ever seen more than 
a transitory drop in the leukocyte and platelet count in 
patients treated with much more massive dosage of the isotope 
for thyroid cancer, where, of course, the dose fraction due 
to radioactive thyroxine is lower.
In thyrotoxicosis, there is a release of radioactive 
thyroxine into the circulation and Courrier, Horeajt, Marois 
and Morel (1949) found some accumulation of radioactive 
thyroxine in the pituitary gland, and in one human case that 
came to autopsy after a large dose of radioactive iodine,
Chapman (1948) found of the isotope in the pituitary.
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Gorbman (l950) noted, moreover, the development of non- 
invasive chromophobe adenomas of the Anterior pituitary 
about 8 months after thyroid-lethal doses of radioactive 
iodine in most of his treated mice.
Goldberg and Chaikoff (1950) have shown that 
such changes cannot be produced in dogs nor in rats, and 
the same workers (1951) proved that feeding of thyroid extract 
to the irradiated mice prevents the development of the 
pituitary changes. It is probable, therefore, that they are 
a compensatory hypertrophy due to the production of complete 
hypothyroidism in the mice. Similar changes have not been 
observed in man. Trunnell, Duffy, Godwin, Peacock and 
Kirsehner, and Hill (1950) in a study of the distribution 
of radioactive iodine, did not reveal a high concentration 
of radioactive iodine in the pituitary, nor did they find 
histological changes in the pituitary following high doses.
Kurland, Ohamovitz, and Freedberg (1950) in a 
very similar study found no histological changes in any 
organ except the thyroid gland.
After careful consideration of all the available 
evidence, 1 feel that there is only very little chance of 
any labe effects resulting from the radiation of radio­
active iodine. Because of its possibility, however, it 
is probably wise meanwhile to reserve this form of 
treatment, in uncomplicated and previously untreated case, 
for patients in the older age groups. Where, however, 
there are any factors which increase the risks of operation,
or in any way unduly complicate treatment with methyl 
thiouracil the remote danger of irradiation hazards should 
he balanced against the risks and inconveniences involved in 
either of the more traditional forms of therapy. I believe 
that in isudh cases the simplicity and efficiency of radio­
active iodine therapy, especially from the patient’s view­
point is such that any theoretical objections to its use 
can be discounted. This especially applies in the treatment 
of thyrotoxicosis after thyroidectdtey, where antithyroid drugs 
are in any case less likely to obtain permanent remission, 
and further operation is notoriously unsatisfactory. For 
such cases radioactive iodine therapy is the treatment of 
choice at all ages.
The above remarks refer chiefly to the use of 
radioactive iodine in the treatment of thyrotoxicosis with 
diffuse gland enlargement. In the case of toxic nodular 
go itre, with large glands, surgery is probably the treatment 
of choice unless, as in case 3, other factors make the 
patient a bad surgical risk; in such circumstances a 
satisfactory remission in symptoms can be obtained with 
radioactive iodine, although somewhat larger doses of the 
isotope are required.
Furthermore, it must be appreciated that radioactive 
iodine "is not suitable for the immediate treatment of patients 
who are critically ill, or who have such complications as 
thyrotoxic heart failure. For such cases, conventional 
medical methods of treatment are necessary before the use of
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radioactive iodine can be considered, although, UK in the 
case of patients with heart failure, subsequent radioactive 
therapy is to be greatly preferred to any therapeutic 
procedure.
There are other factors which still limit the 
more general application of this technique to the treatment 
of thyrotoxicosis. Expensive and elaborate equipment is 
necessary if administration of the isotope is to be on a 
scientific basis, and not merely a matter of guess work.
The close collaboration of physicians, radiotherapists, 
and physicists is necessary, and such team-work is only 
possible in a few centres. Consequently, the treatment 
can only be available in certain places, and can not be 
applied yet as a domicilif&y form of treatment in outlying 
districts or in less well equipped hospitals.
The other factor which at present necessitates 
caution in the application of this form of treatment in 
this country is lack of knowledge regarding the precise 
dosage administered. As already pointed out, the 
calculated dosage is based on a formula involving the gland 
uptake of the isotope, biological half life in the gland , 
and the weight of the gland itself. If the treatment is to 
be rational and scientific, as close an estimate as possible 
should be made beforehand of the dose necessary for each 
patient. Half life and uptake can be, and should be, 
determined for each patient before treatment and as close an 
estimate as is possible made of the size of the gland.
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Some American groups have tried to evolve short cuts to 
dosage assessment such as by gland size alone, (Williams, 
Jaffe, Towery, Rogers, and Tagnon, 1949); level of toxicity 
and gland size, (Gordon and Albright, 1950) Feitelberg 
and his co-workers (1950) assume a biological half life 
in their dosage assessment of 6 days, an assumption which 
study of Table v shows to be unwarranted.
Hursh and Karr (1951) summarise three techniques: 
in use in the United States to assess dosage.
(1) Administration of a constant basic small 
dose to all patients, the treatment being 
repeated until remission is achieved.
(2) Administration of an oral dose calculated on 
the basis of a constant number of microcuries 
per gram of estimated thyroid gland weight.
This custom neglects variabilities in gland 
absorption, half life, and errors in weight 
estimation.
(3) Administration of a constant number of 
microcuries taken up by the thyroid per gram 
of weight. This method is the best of the 
three, but it also omits measurement of half 
life, and again gland size estimation is by 
palpation.
to
These writers go so far as to reduce/the.terms 
of a nomogram the calculation of the necessary oral dose 
in millicuries necessary to deliver a dose of 10,000 e.r. to 
a gland of estimated weight which has a known observed uptake 
of iodine, the bioloffigal half life being assumed to be 
6 days.
When a few additional preliminary gland 
observations during the tracer dose study allow the 
biological, and hence the total, half life to be calculated ;
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when by the technique described it is possible to obtain 
an objective estimation of gland size; and when the percentage 
uptake of the isotope is simply determined during the tracer 
investigations, it would appear to be unnecessary to make 
inaccurate assumptions in the assessment of dosage.
These devices, while simple, do not permit of the 
best possible use being made of the isotope, and the aim of 
treatment should be to cure the patient with a simgle dose.
Some centres, however, prefer to administer 
intentionally small doses, and give repeated drinks of the 
isotope, to avoid the possibility of hypothyroidism or 
myxoedema. The risk of the latter event is probably less 
than the necessary prolongation of the period of hyperthyroidism 
which is implicit in the policy of the administration of 
repeated small doses. Where dosimetry cannot be precise, it 
is certainly preferable to give smaller doses with the 
knowledge that failure to obtain a remission can always be 
remedied by administration of a further dose. When gland 
size can be accurately predetermined by further development 
of the technique described earlier, the last unknown factor 
in calculation of the dose will have been eliminated, and the 
necessity for further doses with the corresponding saving in 
time off work and in hospital beds occupied, should be 
infrequent.
Experience with this small series of cases, and 
with subsequent cases treated, has convinced those of us 
working in Sheffield of the many advantages of this form of
therapy. With further experience and the development of new 
techniques, it will become a method of treatment for thyro­
toxicosis suitable for many more cases of this disease than
those for whom it is now recomended and used with confidence.
>
2. The Treatment of Carcinoma of the Thyroid.
Radioactive iodine has not nearly such a well 
established place in the treatment of carcinoma as it has 
gained in the treatment of thyrotoxicosis. This is chiefly 
because such a small proportion of carcinomata of the thyroid 
exhibit the physical property of being able to concentrate 
iodine, this property being essential if the isotope is to 
be of any value in the treatment of the condition.
Frantz, Ball, Keston and Palmer (1944) were the 
first workers to demonstrate selective concentration of 
radioactive iodine in a thyroid carcinoma, and their first 
cases were all cases of " adenoma malignum". Subsequent 
work has shown that the only types of thyroid carcinoma which 
can concentrate iodine are some of those with a follicular 
structure, such as some varieties of adenocarcinoma. 
Undifferentiated carcinoma and papillary carcinoma do not 
concentrate the isotope. Where, however, the isotope can be 
concentrated in the primary or metastatic growth, it has some 
theraputic value, and the progress of the growth can be 
arrested and life prolonged. In a recent review of the 
subject, Rawson and Trunnell (1951) with a very considerable 
experience, state that notwithstanding the fact that they have 
observed ’tumorcidal’ effects of irradiation delivered by
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radioactive iodine, they have not observed any cures of 
cancer of the thyroid in patients treated with the isotope.
A considerable literature has accumulated regarding 
this application of the isotope, and Paterson (1950) and 
Warrington (1950) have reported on its use in this country.
In addition to the fundamental work, chiefl# with 
autoradiographic techniques, in elucidating the biological 
characteristics of thyroid carcinoma, most work has concen­
trated on methods by which tumor deposits can be induced to 
concen^ra^e administered iodine when they have not initially 
shown this property, for thereby the field of application of 
the isotope can be broadened.
When the radioactive iodine is administered it is 
selectively concentrated by residual normal functioning 
thyroid cells, and, unless there are metastatic deposits in 
glands or bone distant from the primary growth, it is not 
easy to detect by in vivo counting the presence Of any of 
the isotope in the malignant tissue. When, however, there 
is a bony metastasis in, say, the skull, collinated counting 
techniques can be applied to detect its presence. Where 
possible, a biopsy specimen should be taken following a 
tracer dose - which may be of a large order, - and the distri­
bution of the radioactive iodine in the normal and cancerous
tissues studied by autoradiography. By the combination of
in
this ..-'technique with/vivo counting, the probability of the 
value of the isotope can be assessed for each ease.
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The primary treatment for any carcinoma should be 
the removal of the growth in tne gland, and of as much of the 
normal gland as possible. An administered tracer doae 
subsequently cannot therefore be collected in the thyroid and 
is all excreted unless retained in metastatic deposits where 
it may be detected with a Geiger counter. It has oeen claimed 
by Seidlin,.Rossman, Oshry, and Seigel (1949) that removal of 
the thyroid increases the output of thyrotropic hormone by the 
pituitary which may stimulate previously non-functional meta­
static growth to concentrate iodine, and this does in fact 
appear to occur, although Paterson (1950) has not noted it in 
any of the cases studied in Manchester.
Rawson and Trunnell (1951) have found that following 
thyroidectomy the percentage pick-up of a dose of the isotope 
by a metastasis may increase tenfold, and in a case studied in 
Sheffield, (Blomfield,1950) we noted a slight increase in the 
uptake in a femoral metastasis, following thyroidectomy, from 
5% to 8.5%, and in Case D.C., described later, uptake in glandu­
lar masses increased from an amount that was just appreciable 
to a total of 33% of the dose after ablation of the thyroid.
Thyrotropic hormone (T.S.H.) can also be administered 
to encourage increased uptake of the isotope, but Warrington 
(1950) has found it of little value, although Rawson and 
Trunnell (1951) have reported a fourfold increase in the 
uptake in metastases following its use. The same workers 
conclude that the most effective way of increasing primary and 
metastatic iodine uptake is to administer a thiouracil .group
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drug for long periods of time, and this, in their hands, has 
been the most useful measure used.
In the management of a case of tl$?oid carcinoma, the 
possibility of the use of radioactive iodine should be considered 
as a palliative, and possibly as a potentially durative measure, 
in any case with metastasetfprovided that the primary growth can 
be effectively dealt with by surgery or by X ray therapy. The 
first step should be ablation of the thyroid by surgery or with 
large doses of radioactive iodine, and subsequently further doses
administered,following the use of methyl thiouracil.  in large
doses for some months. If evidence appears of any retention in 
the body of any of the dose of the isotope, this must be taken 
as evidence of residual iodine - concentrating tissue, which 
may be tumouJr tissue. Subsequent dosage should be as high as 
can be tolerated.
The problem of accompanying toxic effects following 
the large doses used, (perhaps over 100 mill&curies) becomes 
real, whereas it is negligible in the treatment of thyrotoxi­
cosis. There may be initial slight radiation sickness, and 
Rawson and Trunnell (1951) have had patients with severe or 
fatal leukopenia. In a patient in Sheffield a thrombocytopenia 
with purpura was a delayed, but temporary, result. These 
workers also noted amenorrhea occurring in a patient, and this 
is due to the very high blood dose that results. They adjust 
their dosage|so that under average circumstances, a blood dose 
of under 100 e.r. is delivered.
It can be seer; therefore, that only exceptionally 
can radioactive iodine be used therapeutically for thyroid
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carcinoma, but in the rare case where it is applicable, 
apparently satisfactory results can be obtained, at least 
temporarily, and, in this country Pochin (1950) has reported 
the considerable resolution of pulmonary metatases following 
the use of the isotope, where it had been shown that a high 
percentage of the dose was concentrated in the lungs.
Oases Studied.
During the past few years some 30 cases of thyroid 
carcinoma have been seen and investigated with radioactive 
iodine in cooperation with Mr. G-. W. Blomfield, Medical 
Director of the Sheffield National Centre for Radiotherapy, 
and of these only 4 cases were found to concentrate iodine in 
the primary or metastatic tumour to the extent that made 
therapjs practicable. In one case, an old lady of 60, 
reported by Blomfield (1950,) initial sclerosis was induced 
in a large femoral metastasis after thyroidectomy and the 
administration of a total of about 320 millicuries of radio­
active iodine. Purpura with thrombocytopenia followed the 
last dose of the isotope, but was only temporary.
Two of the other cases are of considerably interest 
as the first, Miss D.C., illustrates the considerable poten­
tialities of the technique 6n the rare occasions when it is 
applicable; the second Mrs.N.B., illustrates the use of the 
isotope in the elucidation of an unusual clinical picture, 
and it also shows how the isotope may fail in its purpose 
although at first it may appear to be of value.
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Oase Report 1. Miss D.C.,Age 18.
This girl had good general health until 1945 when 
she first noted a hard painless swelling on the right side 
of her neck, to which she paid little attention. In August 
1949 a further painless swelling was noted below the right ear 
and she consulted her doctor in October 1949. Biopsy showed 
the swelling to be due to lymphatic involvement with metastatic 
thyroid adenocarcinoma.
On admission to hospital she had no symptom referable 
to the swellings, and, apart from their presence, was healthy 
in every way. The left lobe of the thyroid was enlarged, and 
firm, but not fixed. There was a large fixed mass of inlands 
at the apex of the right lobd of the thyroid, and a further 
mass of blands was palpable above the left clavicle.
Clinically she was otherwise normal, was in normal 
thyroid balance, and all haematological,biochemical,and 
radiological investigations were normal.
A tracer dose of 114 microcuries of radioactive 
iodine was given which demonstrated normal thyroid function. 
Search with a collimated counter showed rather less absorption 
in the left lobe of the thyroid, the glands above the left 
clavicle did not appear to concentrate iodine, but there was 
appreciably increased activity in the felands below the right 
ear, compared to:the activity present at a similar site on 
the left.
Accordingly, following another tracer dose, an 
operation was performed on 13/2/50 in an attempt to eradicate
Figure 30. Diagram of lines of equal counting rate over functioning 
thyroid metastases, after previous ablation of the thyroid gland. 
Case, Miss D.C.
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as much as possible of the primary and metastatic deposits.
A left thyroidectomy was performed, but because of the 
infiltrating nature of the disease, the widespread glandular 
involvement that was demonstrated, and the involvement of the 
recurrent laryngeal nerve in glandular enlargement, the Surgeon 
was unable to remove the right lobe, nor resect the glands on 
the right side of the neck or above the left clavicle. Auto­
radiography of sections from the excised glands showed iodine 
concentration in the malignant tissue, and direct assay of the 
specimens showed a specific activity of up to 0.7 microcuries 
per gram of tissue.
On 4/3/50 a dose of 30 milicuries of radioactive 
iodine was given which was practically all concentrated in the 
right side of the neck, and delivered an$r estimated 36,000 e.r. 
to the res idua-| thyroid tissue. Following this dose her 
condition remained excellent, her weight stationary, and there 
was no clinical evidence of myxoedema, and her blood cholesterol 
only rose from 215 mg.$ to 260 mg.$
On 17/5/50 a larger tracer dose of 5 millicuries 
was given. There was no uptake at the normal site of the 
thyroid, 23$ was taken up into the left supraclavicular 
glands, and 33$ into the glands below the right ear, the 
24 hour urine excretion being 40$. Figure 30 shows the dis­
tribution of the lines of equal counting rate over these two 
masses and demonstrates the absence of appreciable concentration 
over the thyroid area itself.
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Accordingly, on the 14/6/50 a total of 67 militaries 
was given to the patient which was concentrated entirely in the 
glandular masses, which were calculated to be 15 grams in weight 
above the clavicle, and 22 grams under the ear, and the delivered 
roentgen dosage following this therapeutic dose was 16,000 e.r. 
and 11,000 e.r, to the two masses respectively. Following this 
dose a detailed search with a collimated counter was made of the 
whole body and skeleton, but no appreciable take up elsewhere 
could be detected.
There were no clinical adverse effects consequent to 
this high dosage. The total blood dose was estimated to be 
only 14 e.r.,as the blood concentration remained low, in 
contradistinction to the high concentrations reached in the 
treatment of thyrotoxic patients. (Figure 4 and Table IX).
There was no demonstrable effect upon her haemopoietiio system, 
and he** menses were uhaffected.
Her weight rose steadily from 9 stone to 10 st.10 lbs; 
clinical evidence of hypothj^oidism developed and her blood 
cholesterol rose to 440 mg.$. Thyroxins therapy was instituted 
and maintained subsequently at 0.3mg.per day, and her blood 
cholesterol fell to 250 mg.$
There was a progressive diminution in eize of the 
large glandular masses, and by 23/11/50 no abnormal glands 
could be palpated anywhere by any observer, and none have
since recurred.
Her general clinical condition is excellent, she
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is taking thyroxine in maintenance dosage, and her future 
management will entail repeated radioactive iodine tracer 
examinations to ensure that there is no retention of the 
isotope; any such retention could only be in malignant tissue, 
and further large doses would be expected to destroy any 
recurrence.
Conclusion; This case illustrates the ?/ay by which apparently 
gross carcinomatous infiltration in a suitable case can be 
radically and completely extirpated, with no systemic adverse 
reacbion.
Cage Report 2. Mrs. N.B. Aged 67.
This patient had good health until 1943 when partial 
thyroidectomy was performed for presumed thyrotoxicosis, but 
section of the specimen, showed the presence of adenocarcinoma. 
In December 1945 nodular masses were apparent in the midline, 
to the right, and to the left, and there was fixation of the 
left vocal cord; biopsy revealed adenocarcinoma and X ray of 
chest showed no evidence of pulmonary metastatic spread.
She was given Deep X ray therapy in 1946 to a total 
of 3,000 r.deep dose and the masses resolved considerably to be 
replaced by induration. She remained well until November 1950 
when she had a severe haemoptysis, and was found to have a 
fixed hard thyroid swelling, and chest X ray showed an upper 
mediastinal mass and multiple secondaries throughout both lung 
fields.
A tracer dose investigation showed uptake of
Figure Jl. Radiograph of chest of Case Mrs. K.B. showing mediastinal
secondary with metastatic deposits in lung fields. Superimposed
on the X-ray are the lines of equal counting rate from radioactive 
iodine. Rote the coincidence of the lines representing greater
activity with the shadows of the metastases.
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radioactive iodine in both the thyroid region (36$) and over 
the pulmonary and mediastinal masses (23%'), urine excretion 
being 20ft* The plot of the lines of equal counting rate showed 
a correspondence of areas of high activity with the observed 
radiological opacities, (Figure 31) which indicated significant 
iodine concentration in the secondaries. Accordingly a dose 
of 93 millicuries was given on 13/12/50 which delivered 3^000 e.r. 
to the thyroid and 9,000 e.r. to the secondaries.
No systemic reaction occurred and theye was no further 
alteration in the secondaries, and a few months later, before 
a further dose had been given, the patient sustained a patholog­
ical fracture through the neck of her femur. Examination
following a further tracer dose showed no concentration of the
>
isotope at this site, and she is currently receiving further 
radioactive iodine therapy directed at her pulmonary lesions, 
which appear to have diminished slightly in size, and deep X ray 
therapy to her hip.
Conclusion; This case illustrates the difficulty of the 
application of the isotope even to those cases where initial 
experience suggests it may be helpful. Some, but not all, of 
the metastases have iodine concentrating- capacity:,; and X ray 
therapy is necessary as well in an attempt to cure the disease.
3. Thfi Therapeutic Induction of Myxoedema.
A recognised treatment for both intractable cardiac 
failure and for severe angina pectoris has been the production 
of hypothyroidism either by total thyroidectomy (Blumgart,
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Levine and Berlin,1931) or by the use of methyl thiouracil 
(Ben Asher,1947; Sharpey-Shafer,1946). Both these methods 
have their disadvantages, especially inasmuch as thyroidectomy 
is a serious operation to contemplate in a person whose clinical 
condition is so precarious that the operation is considered 
justifiable. Further, it is difficult and requires long and 
high dosage therapy to induce myxoedema with methyl thiouracil, 
and the advantages of the procedure are questionable, although 
some patients undoubtedly benefit by it. Firstbrook (1951) 
seriously questions its use for angina because of the resultant 
probable acceleration of the underlying atherosclerotic process.
The advent of radioactive iodine has provided a simple, 
safe, and effective means of intentionally ablating all thyroid 
tissue and a large number of cases have been treated in this 
fashion, especially by Freedberg, Blumgart, Kurland, and Chamovitz 
(1950).
Little experience of this use of radioactive iodine 
has been gained in this country, but three suitable cases have 
been treated in Sheffield, one with considerable benefit, and 
two with equivocal results.
Case Report 3* Mr.A.W. - Aged 59.
This patient presented in March 1951 with a two-year 
history of typical angina pectoris, becoming very much worse in 
the previous two months, and on admission to hospital he had 
frequent angina at rest.
On examination he was slightly obese, and his blood
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pressure was 160/100; clinical examination and ancillary 
investigations, with the exception of his electrocardiogram, 
were normal. This electrocardiogram showed minimal evidence 
ofcoronary insufficiency at rest, but on exercise over standard 
exercise tolerance test steps only 18 efforts could be made; 
this produced a severe attack of angina with gross electro­
cardiographic changes, there being marked S T segment depression 
in the standard and left precordial leads.
This condition was regarded as being very severe, and 
accordingly a dose of 23 millicuries of radioactive iodine was 
given on 6/4/51 delivering 20000 e.r. to the gland. His 
clinical condition improved during the next six weeks in a 
most remarkable fashion, and clinical evidence of myxoedema 
was apparent by June 1951, by which time his blood cholesterol 
had risen from 264 mg% to 540mg^‘, and there were typical 
changes of hypothyroidism in his electrocardiogram. ..His 
exercise tolerancd increased immeasurably,, and by July there 
was no limit to the distance he could walk at a regular rate, 
unless the weather was unduly cold. His requirement for 
trinitroglycerin tablets dropped to zero from a high level, 
and he himself has been emphatic that his second state of 
fairly advanced myxoedema is to be greatly preferred to his 
previous painful, and miserable existence with angina decubitus. 
Conclusion: in certain selected cases the isotope can be used
to induce myxoedema therapeutically with great ease and 
efficiency, and with considerable benefit to the patient.
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Final Summarized Conclusions.
The work described in this Thesis has shown that 
in addition to fundamental information regarding the physiology, 
and the pathological physiology, of thyroid function, the 
advent of radioactive iodine has provided the means wherewith 
certain useful and valuable diagnostic and therapeutic 
techniques can be developed.
It has been shown that objective evidence of 
disturbed thyroid function is given by study of the amount 
and rate of uptake of the isotope, and of the amount that is 
converted into protein-bound form as thyroxine. Tests of 
this nature provide evidence of a correlation between clinical 
thyrotoxicosis and certain definite departures from the normal 
results of the tests. It has been shown that the uptake of 
the isotope into the gland after 4 hours is commonly under 
40# in the presence of normal thyroid function, and in excess 
of that figure in thyrotoxicosis. Thyroid iodide clearance 
rates from plasma are commonly over 80 ml per minute in the 
presence of thyrotoxicosis, but lower rates can be encountered^ 
and this test is less valuable in many instances as a diagnostic 
screening procedure.
It was concluded that on the basis of the series here 
reported an estimation of the protein-bound plasma activity 
after 48 hours provides the most consistently reliable diagnostic 
information, thyrotoxicosis being practically always associated 
with levels in excess of o.4 per cent of the dose per litre of 
plasma. Conversely, normal thyroid function was characterized
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by levels below 0.4# per litre, and usually below 0.1# per 
litre. In a few cases studied after fairly recent successful 
treatment, persistent high levels of 48 hour protein bound 
plasma activity were encountered in the presence of clinically 
normal thyroid function.
Hypothyroidism was probably best diagnosed with 
radioactive iodine on the basis of a high urinary excretion 
after 2 days, and it has been shown that the isotope has a 
small but significant field of usefulness in the diagnosis of 
the site of aberrant functioning thyroid tissue and of carcinoma.
In the therapeutic field, very satisfactory results 
with no significant complications or disadvantages, have been 
achieved in the treatment of thyrotoxicosis, and it has been 
concluded that the risks of the use of the isotope are negli­
gibly compared to the value of utilising the efficiency, 
safety, and simplicity of the technique as a therapeutic pro­
cedure. Furthermore, it has been shown that with care, and 
with full preliminary study of all variable factors on which 
dosage depends, accurate estimates can be made of the size of 
the drink in millicuriesto be given to the patient in the 
knowledge that such a drink will deliver the optimum roentgen
dosage to the gLand.
In rare selected and suitable cases radioactive 
iodine can produce dramatic results in the treatment of 
carcinoma of the thyroid, and it can also be usefully applied 
to induce myxoedema as a therapeutic measure for angina
pectoris and for intractable congestive cardiac failure.
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Aupendlx I 
Normal Gases. Part A 
1* CLINICAL DETAILS
Case
No*
Sex Age B.M.R.
cb
Blood chol.
mg. ja
Remarks
1 F 50 - Sarcoidois
2 M 4S -16 - Degenerative 
auricular fibrillation
3 F 44 - - Mitral stenosis 
Rheumatoid arthritis
4 M 37 - Auricular fibrillation
5 M 33 mm - Mitral stenosis
6 M 6o - - Qphthalmoplegi a
7 F 64 4 240 Parkinson!sm
8 F S * Mitral stenosis
9 F 64 «■» - Pernicious anaemia
10 M 45 - mm Mitral stenosis
li M 34 mm 210 Dermatitis herpetiformis
12 M 57 0 210 Dementia
13 F 37 - - Mitral stenosis
14 F 30 -11 255 Obesity
15 F 44 -1 250 Obesity
16 M 6o ‘ 13 300 Ophthalmoplegia
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Appendix I (cont.)
Normal Cases. Part A.
2. RESULTS OF RADIOACTIVE IQDIEE TESTS 
Case Gland uptake, $ Time to Biol. -g 24 hr. Thyroid 48 hr. plasma
TT—. A 1ama a. *D a. rt A 1a . *L_ m a 1 2 >^a *• ■»! m a am mis a «vj «•
(mins.) (days) rate
ml./min.
Total Protein bound 
io dose/litre
1 24 54 53 280 - 20.5 22 - -
2 14 31 29 308 - 44.5 18 neg. neg.
3 11 26 26 360 2.3 59.5 10 0.19 -
4 17.5 35 32 260 A 48.0 19 0.1 neg.
5 8 21.5 19 480 - 51.8 11 0.12 neg.
6 18 34 34 210 32 44.0 23 0.14 neg.
7 14.5 24 24 126 15.8 - 13 0.64 neg.
8 21 45 40 300 50.0 30 - -
9 24 51 53 268 - 43.0 35 0.2 neg.
10 24 47 42 260 A 33.0 30 A -
li 18.5 37.5 34 250 55.7 38 neg. neg.
12 13 34 31 390 53.0 15 0.07 neg.
13 9.2 - - 280 - 59.5 - - -
14 26 53 53 260 4.6 37.0 46 neg. neg.
15 l6 3 34 282 15.4 52.3 23 neg. neg.
16 18 49 46 380 17.7 40.2 26 neg. neg.
neg. r negligible activity.
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Appendis II
Intermediate Croup Cages. Part A 
1. CLIMCAL DETAILS
3ase
la.
Sex Age
>
Blood chol. 
mg. ^
Bemarks
17 F 45 - 300 Thyroidectomy, 1947- 
Auricular fibrillation.
IS F 4S - 290 Thyroidectomy, 1942.
19 F 45 36 210 Large non-toxic goitre.
20 F 41 24 • - Noi>-toxic goitre and 
anxiety state.
21 F 37 10 210 Non-toxic goitre and 
anxiety state.
22 F 32 2 230 Snail non-toxic goitre 
and anxiety state.(D)
23 F 39 IS 200 Large non-toxic goitre. 
Treated by operation.
24 M 20 3 200 Small no nr-toxic goitre 
and anxiety state. (D)
25 F 6i -11 210 Hour-'toxi c goitre. Anxi ety 
state. Essential hypertension.
26 F 63 -27 320 Old thyrotoxicosis in 
remission. Essential hypertension.
27 F 39 27 375 Anxiety state superimposed 
on old thyrotoxicosis.
23 F 53 2 240 Anxiety state.
29 F 47 210 Anxiety state. (D)
30 F 27 0 200 Simple non-toxic adenoma.
31 F 32 -IS 225 Anxiety state.
(D) - Case in “Doubtful 
Figures 15,
non-toxic,f category in 
l6, and 17.
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Appendix II (cont.)
Intermediate Group Cases. Part A
2. HBSULTS OF BADIQASTIVS IQDIHS TESTS
Case G-land uptake, i» Time to Biol. 3 24 hr. Thyroid 48 hr. plasma
Ho. A hrs. Peak 24 hr. i- peak life urine clearance activity
(mins.) (days) ft rate Total Protein-bound
ml./min. ft dose/litre
17 26.5 60 58 £S - 30.5 35 - -
IS 24.5 43 41 ISO ** 50 20 - -
19 30 46 46 132 22 31.8 3 0.29 0.15
20 48.5 69 6S 110 inf. 32. S 45 0.13 neg.
21 11 24 23.5 260 5 6l 10 neg. neg.
22 31.3 58 58 216 - 27 29 - -
23 31 42.5 42 130 14 40.5 38 0.32 • -
24 26 48 45.5 220 5.1 40.5 56 neg. neg.
25 19 42 40 316 - 35 20 0.1S neg.
26 25 47 47 410 23.5 53.5 IS 0.4 0.4
27 23 41.5 41.5 170 24 48.5 30 neg. neg.
2S 17.5 33 33 238 116 50.S 23.5 1.16 neg.
29 2S.5 . 48 48 162 15.4 37 25 0.3 -
30 34 52 50 153 inf. 40 59 0.1 neg.
31 40 58 56 146 13 32 58 0.16 —
neg. = negligible activity.
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Atroe ndix II (co nt.) 
Intermediate Q-roup Cases. Part A 
1. CLINICAL DETAILS (continued)
)ase
!o.
Sex Ag© M A Blood chol.
mg* £
Hemarks
32 P 47 - - Thyrotoxicosis in remissicn 
and anxiety state.
33 P 31 - 290 Non-toxic adenoma and 
anxiety state.
34 P IS 0 150 Small non-toxic goitre.
35 P 33 -18 270 Non-toxic goitre.
36 P 28 -3 320 Small non-toxic goitre 
and anxiety state. (D)
37 P 20 20 . 190 Non-toxic goitre and 
anxiety state. (D)
38 M 32 20 140 Invalided from E.A.P. 1942 
with thyrotoxicosis. (D)
39 P 27 -3 183 Non-toxic goitre. Thyro­
toxicosis ? diagnosed 1942.
40 P 37 - 270 Anxiety state.
41 P 55 - - Non-toxic goitre.
42 - P 37 330 Anxi ety state.
43 P 42 - 280 Simple non-toxic adenoma.
44 P : 33 -3 320 Thyroidectomy 194&. 
Anxiety state. (D)
45 P 62 -3 - Non-toxic goitre.
46 P 46 - 3*$ Thyrotoxicosis in 
remission. Anxiety state.
(D) = Case in "Doubtful non-toxic 
Pigures 15> l6, and 17
" category in 
•
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Appendlx II (cont.)
Intermediate Croup Cases. Part A
2. BBSULTS OF BAPIQACTIVS IODINE TESTS (cont.)
Case Grland uptake, p Time to Biol. -g 24 hr. Thyroid 48 hr. plasma
No. A hr s. Peak 24 hr. k reak life urine clearance activity
(mins•) (days) p rate Total Proteln-bound
ml./min, cp dose/litre
32 20 42 38 240 - 47.5 — — —
33 23 42 38 iso - 48.9 39 0.26 neg.
34 20 47 46.5 300 - 41 - - -
35 20.5 43 43 280 40 41 45 - -
36 37 58 57 186 12 33.1 71 neg. neg.
37 40 64.5 64.5 146 70 24 69 0.18 neg.
38 32 50 50 171 19.6 38.4 56 0.1 0.09
39 17 42 36 310 - 48.4 17 neg. neg.
40 20 46 441 r 286 - 40.S 31 0.19 neg.
41 16.5 37 35 310 - 49.6 18 neg. neg.
42 31 49 49 145 - 48.8 30 0.1 neg.
43 23 43 43 212 - 52.3 21 0.2 neg.
44 39 56.5 56.5 108 9.5 32 60 0.44 0.35
45 25 54 54 226 30 37.8 31 neg. neg.
46 27.5 55.5 55.5 238 14.8 40 39 neg. neg.
neg. - negligible activity.
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Appendix III
Diffuse thyrotoxicosis cases* Part A
1. CLIMCAL DETAILS
Case Sex Age Grade of B.M.R. Blood chol. Treatment Remarks
Ho. toxicity $ * mg.
51 . F 34 4 66 150 M.T. -
52 F 57 4 56 210 I131 -
53 f as 2 10 1S5 Op. -
54 F 53 2 33 230 M.T. Later got 
carcinoma thyroid.
55 F 55 2 3 250 1131 Auricular
fibrillation.
56 F 33 3 60 200 Op. -
57 F 38 3 24 - M.T. -
58 F 58 3 53 190 1131 Previous failure 
with M.T.
59 F 22 3 2 275 Op. Failure with 
M.T.
60 F 39 3 40 155 1131 Very large goitre.
61 M 34 3 59 160 M.T. -
62 F 38 1 17 195 M.T. -
63 F 24 4 32 200 Op. -
64 ’ F 20 3 26 205 i13l Previous op. 
and M.T.
65 F 42 4 40 230 lx3l Previous M.T.
66 F 45 4 - - - Died. Congestive 
cardiac failure.
M.T. = methyl thiouracil. 
partial thyroidectomy, 
radioactive iodine.
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Appendix III (cont.)
Diffuse thyrotoxicosis cases. Part A
2, EEiSULTS OP B&DIQi&TIVP IODINE TESTS
Case Gland uptake, jo Time to Biol. J 24 hr. Thyroid 48 hr. plasma
No. 4 hrs. Peak 24 hr. k peak life urine clearance activity
(mins.) (days) % rate Total Protein-bonnd
ml./min. ^ dose/litre
51 SS ss 75.5 2S 3.8 s - - —
52 67 72.5 72.5 6s 33 12.5 - - -
53 57 70.5 70.5 106 13 22.5 100 0.42 0.41
54 62 65 58 90 3.9 n . 9 1S4 2.0 1.35
55 51 - 71 - - 20 - - -
56 SI SS S2 24 s 5 .6 458 0. 6s 0.52
57 60 79 77 90 23 24.3 - - -
58 77 77 65 30 6 5 - - -
59 67 77 77 125 13 16 245 . 1.04 1.06
6o 74 76 73.5 . 24 5 .4 4 .2 383 0. 9s 1.0
6 i 55 72 72 96 16.1 20.S 140 0.24 0.13
62 50 63 62.5 145 5.3 20 97 1.26 1 .(5
63 S0.5 S2.5 76.5 10 10 5.5 560 0.S7 -
64 75.5 75,5 55 37 2 S .6 220 5.5 3 .4
90 90 79 24 7 10.3 226 2.2 1.6
66 73 76.5 71 42 15 15.5 153 - -
Appendix III (cont.)
Diffuse thyrotoxicosis cases. Part A
1. OLmCAL DETAILS (cont.)
Case Sex Age Grade of B.M.R. Blood chol. Treatment Remarks
lo. toxicity 1* mg. *
67 F 31 3 15 150
1131 Also with thrombo­
cytopenic purpura.
6S M 22 4 - 200 Op. Large goitre.
69 M 54 2 34 220 I1* -
70 F 46 4 24 170 1131 Also with hydronephrosis
71 F 28 4 14 220 M.T. -
72 M 3S 3 12 75 I13l -
73 M 49 3 22 230 M.T. -
74 F 47 2 32 200 xl3l Previous op.
73 F 47 2 43 130 ll3l Previous op.
76 F 60 4 so 195 I1^ Malignant exophthalmos
77 F 45 1 -7 190 M.T. -
7S F 33 3 so 175 M.T. -
79 F 36 4 46 230 I1 1^ Previous op.
so F 21 2 49 195 Op. Failed with M.T.
SI F 34 3 - 200 Op. -
S2 M 51 2 42 220 1131 -
S3 F 47 2 29 112 I1*
M.T. « methyl thiouracil.
- partial thyroidectomy,
- radioactive iodine.
i
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Appendix III (cont.)
Diffuse thyrotoxicosis cases. Part A
2. RESULTS OF RADIOACTIVE IODINE TBSTS (cont.)
Case G-land uptake, jo Time to Biol, g 24 hr. Thyroid 48 kr. plasma 
H o . 4  h r  s . P eak 24. hr. h peak life urine clearance activity
(mins.) (days) rate
ml./min.
Total Protein -1 
$ dose/litre
67 so SI 74 50 5 .3 9 123 - -
6s 64.5 70 67.5 41 4.8 3.5 244 O.96 0.74
69 50 6 l 56 100 12.8 21.3 92 1.03 0.S7
70 62 S2.5 S2.5 120 - 15.5 - - -
71 89.5 92 72 27 4.6 10 320 2.9 -
72 6s 77 74 SO 7 10.5 174 1.6 0.91
73 55 72 70 85 8.5 28 67 0.87 0.63
74 4L 57 54.5 104 32 34.5 50 0.64 0.64
75 40 6 i 6l 102 4-7 28.5 30 1.5 1 .2
76 74 75 64 39 5 8.5 270 3.5 2.9
77 55 70 70 117 «N» 23 79 - -
78 89.S 90 72.5 36 2.8 7 £ 0 - -
79 89.5 92 72 67 3.9 S.S 612 2.3 1.6
SO 72 SS 87 90 7.2 3.3 578 0.78 0.61
SI 84.5 89 87 35 - 4.7 885 1.29 o.s6
S2 so S6 78 44 8.5 3.6 833 1.48 1.43
S3 87.5 88 76 48 s.s b 1780 1.77 1.24
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Appendix IV 
Toxic adenoma cases. Part A 
1. CLINICAL DETAILS
Case Sex Age Grade of B.M.R. Blood chol. Treatment Remarks
ISL* toxicity $ mg. f
35 r 55 2 0 195 Op. Auricular
fibrillation.
S6 f 33 2 36 200 Op. Large adenoma.
S7 p 52 1 - 270 Op. Increased concentration 
of 1*31 £n nodule.
ss F 56 3 7 3S0 Op. Large goitre.
89 F 42 1 13 275 Op. Increased concentration 
of 1^31 in nodule.
90 F 65 2 IS 200 Op. -
91 F 73 3 - 140 ix3i Auricular fibrillation 
and congestive failure
92 F 53 1 17 290 1131 Increased concentration 
of 1^31 in nodule.
93 F 26 1 23 140 M.T. -
94 F 56 3 43 Op.
,95 F 53 2 30 165 M.T. Auricular fibrillation
and congestive failure.
M.T. s methyl thiouracil.
Op*.. = partial thyroidectomy.
I ' s radioactive iodine.
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Appendix 17 (cont.)
Toxic adenoma cases. Part A
2. BSSULTS OF BADI CACTI VS IODINE TESTS
Case Gland uptake, ^ Time to Biol, g 24 hr. Thyroid 43 hr. plasma
Ho. 4 hr s. Peak 24 hr, a peak life urine clearance activity
(mins.) (days) $ rate Total Protein-bound
ml./min. cjo dose/litre
85 34.5 56 55 140 31.5 - - -
86 53.5 63.5 63 134 25 31 70 0.25 -
37 G 60 • 60 136 12 21 84 0.74 neg.
88 72 76 76 20 15 3.5 - - -
89 44 62 60 126 16 28 36 1.15 0.82
90 53.5 71.5 63.5 108 6 7.5 36 - -
91 63.5 70 67.5 41 4.3 1.2 330 3.07 2.45
92 62 62 104 14 29 65 0.63 -
93 42.5 64.5 135 - 34 - - -
94 53 62 57 36 4.7 6 - 2.4 l.l
95 50.5 60.5 60.5 77 7 12 89 2.1 1.5
neg. - negligible activity.
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Appendix V 
Mvxoedema. Part A 
1. OLINIOAL DETAILS
B.M.R. Blood chol.
mg.
Remarks
96 P 61 -S 390 Also a diabetic with 
peripheral vascular disease
97 P 59 0 315 -
98 M 62 -42 645 -
99 P 64 -15 420 Also with Raynaud*s 
disease.
2. RESULTS OP RADIOACTIVE IODINE TESTS
Case
No..
01 and uptake,
4 hrs. Peak 24 hr.
Time to 
k peak
Bi ol. a 
life
Urine excretion, $ . 
34 hr*. 48 hr.
(mins.) (days)
96 6 12.5 12.5 280 11.9 46 62
97 4 3.5 - - - -
98 5 8 6.3 - - 43 45
99 10.5 23*4 22.5 260 7.0 56.5 3^*3
96
97
98
99
Thyroid 
clearance rate 
ml. /min.
0.4
34
48 hr. plasma 
activity 
Total Protein-Bound
%/litre
0.4
0.7
neg,
neg.
neg. r negligible activity.
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Appendix VI |
Ion-toxic cases. Part B |
CLmOAL DETAILS RESULTS OF RADIOACTIV1 L.CfPINE TESTS
Case
lo. /O.P.
Sex Age Diagnosis B.M.R.
£
4 kr. 
uptake 
*
Thyroid
clearance
rate
48 hr. 
P.B. activi 
/litre
101 O.P. F 34 I.T.G. 
A. S.
(D)
•M 42 96.S neg.
102 O.P. F 57 H.T.Gr. - 9.5 4.1 neg.
103 O.P. F .46 A. S. - - 27.6 neg.
104 O.P. F 37 A. S. - 11 4 0.16 (x)
105 O.P. F 30 A. S.
(D)
** £5.5 40 neg.
106 O.P. M 65 T.T. - 26 34.7 0.1
107 O.P. F 29 A.S.
(D)
- - 33 neg.
10S O.P. F 23 A. S. - 30.5 46 neg.
109 I.P. M 40 T.T. -12 21 37 neg.
110 O.P. M 33 I.T.G. - 16 17 neg.
ill O.P. F 20 A. S.
(D)
- - 27 0.2 ,(*)
112 I.p. - F 51 N.T.G.
(D)
13 48 56.3 neg.
113 O.P. F 49 JT.T.G. - 25 25.6 neg.
114 O.P. F 38 N.T.O. mm - 61.2 0.3 W
115 I.p. : V 6l N.D.T. - 10 3.8 neg.
116 I.p. F 27 A.S.
(D)
10 43 42.3 0.15
117 O.P. F 30 T.T. - 5.5 2.8 neg.
11S O.P. M 31 A. S.
(D)
- 33.5 68.5 neg •
Appendix VI (cont.)
No Dr* toxic cases (cont.) Part B
CLINICAL DETAILS BESULTS OF RADIQACTIV3S IODINE TESTS
Cage I.P^ Sex Age Diagnosis B.M.R. 4 hr. Thyroid 4# hr.
N o . ft uptake clearance P.B. activity
c/o rate ^/litre
119 O.P. F 25 A.S.
(D)
26 29.4
120 I.P. F 3S N.T.Gr. - 20.5 $.2 neg.
121 I.P. F 37 N.T.G-.
A.S.
- 31 99.4 neg.
122 I.P. F 39 N.D.T. 17 24.5 27 neg.
123 I.P. M 46 ' N.D.T. 4 17.5 10.3 0.18
124 O.P. F 36 N.D.T. - 34 26.9 neg.
125 I.P. F 27 N.D.T. - 18 34.6 neg.
126 I.P. F 69 N.T.O. - 27 IS 0.04 *
127 I.P. F 56 N.D.T. - 11.5 6 neg.
128 O.P. F 28 A.S. — 41 32.4 neg. .
129 O.P. F 42 N.T.Gr. - 31.5 31.4 neg.
130 I.P. F 59 A.S. -2 32 40.7 neg.
131 I.P. M 68 N.T.Gr. -3 10 9.1 neg.
132 O.P. F 54 A.S.
(D)
- 24 27.6 neg.
133 O.P. F 42 N.T.a. - 24 23.6 neg.
134 O.P. M 55 N.T.Gr. - 43.5 113.5 0.1
135 I.P. M 41 A.S.
(D)
7 10.5 9.4 0.17 (x)
136 I.P. M 59 N.D.T. - 21.5 24.7 0.2
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Appendix 71 (cont.)
Ion-toxic cases (cont.) Part B
CLINICAL DETAILS BESULTS OF HADIOACTIVS IODINE TESTS
Case I.P^ Sex Age Diagnosis B.M.B. 4 hr. Thyroid 4# hr.
No. x'^u.P. yo uptake clearance P.B. activity
1° rate litre
137 I.P. F 56 N.D.T. - 20 - -
13S O.P. F 41 N.T.G-. - 21 24 neg.
139 I.P. F 64 N.D.T. - - 0.18
140 O.P. F 3^ A.S.
fl»
- 18 17.6 0.07 (x)
141 O.P. F 36 N.T.Gr.
(B)
- 44 53.2 neg.
142 I.P. F 58 N.D.T. -10 3S 44.2 0.l6 (x)
143 I.P. F 34 A.S.
(B)
15 3S 54.5 0.23
144*TT O.P. F 56 N.T.Gr.
(B)
- 41.5 48.3 0.1 (x)
145 O.P. F 31 T.T.
(B)
- 15 11 neg.
146 I.P. M 52 N.D.T.
(D)
- 22.5 45 neg..
147 O.P. F 26 N.T.Gr.
(B)
- - 37.8 neg.
14S I.p. F 51 A.S.
(B)
21 33 55. S 0.37
149 I.P. F 39 N.T.Gr.
(B)
11 53.5 72 0.16
150 I.P. F 40 N.T.Gr. — 21.5 22.9 0.17
N.T.Gr. Non-toxic goitre, diffuse, colloid, or simple adenoma.
A.S. Anxiety state.
T.T. Thyrotoxicosis treated in the past and in remission.
N.D.T. No disease of thyroid present nor suspected.
LI/O.P. In-patient investigation/Out-patient investigation.
P.B. Protein-bound.
(D) Case included in “Doubtful non-toxic” category in Figures 15-17.
(x) Signifies 4# hr. total activity in plasma.
neg. Negligible activity.__________________   j
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Appendix VII
Toxic cases. Part B
CLINICAL DETAILS BBSULTS OF BADIOACTIVE
IODINE TESTS
Case I.P^ Sex Age Grade B.M.R. Treatment 4 hr. Thyroid 48 hr.
No. /u.P. ^ uptake clearance P.B. activity
3® rate /^litre
ml. /min.
155 I.P. M 51 3 44 Op. 54.5 $ 2 3 .*
156 I.P. M 37 2 28 i 1* 72 308 1.21
157 I.P. F 37 3 15 1131 82.5 411 1.74
158 I.P. F 31 2 22 M.T. 65 144 1.2
159 I.P. F 28 1 4 M.T. 60.5 100 0 .4  (x)
160 I.P. F 65 3 48 I !3 1 76.5 154 0.42
161 I.P. F 67 2 47 l!3 1 40.5 42 0.7 .
162 I.P. M 39 2 - Nil 49 95 0.96
163 I.P. F 39 3 61 M.T. 67 266 0.9
164 I.P. F 55 2 37 1131 75 212 -
165 •I.P. F 67 3 53 ll3 1 79 172 2.®
166 O.P. F 56 1 - Nil 58 153 neg.
167 O.P. M 60 2 - I1^ 62.5 176 0.87
16s i.p. F: 67 2 ll3 1 . 69.5 147 l.i
169 i.p. F 20 3 37 M.T. 83.5 464 0.8
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Appendix VII (cont.)
Toxic cages (cont.) Part B
CLINICAL DETAILS ■ RESULTS OF RADIOACTIVE
IODINE TESTS
Case I.P-^ * Sex Age Grade B.M.R. Treatment 4 Thyroid 4S hr.
No. /U.P. io uptake clearance P.B. activity
•p rate ^/litre
ml./min.
170 1.p. M 4S 3 32 I 74 31s 1.99
171 O.P. F as 2 - 1131 73 245 1.14
172 1.p. F 54 2 2S ll3l 45.5 211 1.46
173 i.p . F 67 3 20 Op. 56 6s 3.17
174 1.p. F 22 2 - 1131 S4 453 0.62
175 i .p . F 4S 2 20 ii3i 46.5 43 0.67
176 1.p. F 31 2 22 1131 5S.5 S3 0.9
177 O.P. F 37 2 - 1131 S3 522 1.24
17S I.p. F 22 3 50 ii3i 76 430 2.67
179 I.P. F 21 3 74 M.T. ss.5 473 0.93
ISO I.p. F 43 1 13 Op. 53 71 neg.
isi O.P. M 41 1 - M.T. 57.5 169 0.43
isa O.P. F 3 2 - M.T. 74 201 1.09
is 3 I.p. F 21 3 - 1131 92 864 2.71
1S4 I.p. F 64 2 - 1131 90 264. 1.7
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Appendix V H  (cont.)
Toxic cages (cont,) Part B
CLINICAL DETAILS RESULTS OF RADIOACTIVE .
IODINE TESTS
Case I.P/* Sex Age Qrade B.M.R. Treatment 4 kr. Thyroid 48 kr.
No. ^/o.P. jto uptake clearance P.B. activity
/b rate ^/litre
ml./min.
1S5 I.p. F 31 2 40 I131 80 361 1.25
186 I.p. F 57 3 63 I13l 93.5 289 3.69
187 I.p. F 26 4 70 M.T. 84 512
188 I.p. F 24 4 50 I1^ 85 636 1.97
189 O.P. F 65 2 - I131 63.5 129 1.47
190 I.p. F 48 2 27 1131 62 101 1.1
191 I.B. F 44 1 18 1131 31.5 41 0.52
192 I.P. F ‘ 12 2 15 M.T. 86 430 2.33
193 O.P. F 55 2 - l!3L 64 138 0.8
P.B. Prote in-hound.
I.P./O.P. In-patient investigation/Out-patient investigation. 
Op. Partial thyroidectomy.
M.T. Methyl thiouracil.
1131 Radioactive iodine,
(x) 48 hr. total plasma activity.
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Appendix VIII
Gases of thyrotoxicosis treated with radioactive iodine.
. M Si H •H >■
»O H
e. pi
0) •
H0 d<H O
U/N•H -—CQ CQ
p«H Si « fli S*'"'*r-< ? 5?^
prH
•H
CO o OS 52? o
J23 « H • MP m 
& .
a,
9
C P 0 0 «2 0) & rH<D <D Pi CQ
Pi Pi OS ftf)rH
U W
<D +? P as d oS
P £
(D09OQ
1 ®fe PVOO H ' • rH O O H E n  O w  -0p
3(DPI
CD
Ii2.H<D335
SWCt, e.r.
1 70 T.F.l 35 12.1.49 5 12,000 21 Fa. 25
2 52 T.F.2 40 9.2.49 4 9,900 24 Eu. 17
3 91 T.F.l 100 (E) 4.3.49
21.6.49
22.6.50
4.5
13.7
14.2
6,000
S,500
10,550 7 I 6
4 76 T.F.l 60 19.7.49
29.9.49
8.7
15.8
0 0
 
0 0
60 
I*'* 
<\ 
. 
1—1 \_0 IS Fa. 34
5 64 R.T. SO 27.10.49
5.6.50
7.5
23.7
I,930
II,600 12 Hy. 2S
6 74 R.T. 40 is.11.49 5.5 6,900 IS Eu. 16
7 75. R.T. 30 30.11.49 5.9 7,700 IS Fa. 15
s 55 R.T. 40 20.12.49 6.9 15,700 IS Fa. 4
9 72 T.F.l 30 3.1.50 5.1 9,500 IS Fa. 47
10 6o T.F.2 90 4.1.50
5.4.50
12.5
20
10.600
11.600 12 Fa. 4
n 92 T.F. 60 (N) 1.2.50 6.5 6,600 17 Fa. 13
12 65 T.F.2 50 22.3.50 8.7 S ,200 12 Fa. . 21
13 69 T.F.3 50 20.4.50 6.2 7,400 12 Ea. 14
•14 79 R.T. 50 24.5.50 7 6,200 13 Fa. 17
15 S2 T.F. 40 IS.7.50 5 13,600 10 Fa. 13
16 S3 T.F. 60 15.S.50 8.4 11,000 10 Ea. 43
17 170 T .10* 60 14.9.50 11.s 12,700 9 I IS
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19
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22
23
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25 
26 
27 
2S
29
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T.F.
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Appendix VIII (cont.)
Oases of thyrotoxicosis treated with radioactive iodine (cont.)
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rn.c. e.r.
164 T.F.3 40 Or) 21.9.50 4.2 9,700 9 Su. 27
160 T.S. 35 27.9.50 4.5 12,700 9 Eu. 33
5S T.F.3 60
40
4.10.50
*•5.51
4
5.5
5,600
2,770 2 Eu. 6
156 T.E. 50 2.11.50 6.4 9,ioo S Eu. 23
157 R.T. 50 30.11.50 4 10,SQQ 7 I 14
167 T.F.3 30 19.12.50 5 S,S0Q 6 I 6
161 T.F.3 40 Or) 25.1.51 7 13,500 5 I 14
176 T.F.l 30 31.1.51 3.1 7,330 4 Eu. 9
175 T.F.l 35 6.2.51 4.7 8,500 4 I -2
165 R.T. 35 14.2.51 6.6 9,200 4 I 9
171 R.T. 33 5.4.51 5.5 6,700 3 I 6
16s T.E. 70 Or) 6.4.51 7.7 7,500 3 Eu. 19
174 T.E. 60 13.4.51 5.2 10,200 2 Eu. 6
Recurrent thyrotoxicosis following operation.
Relapse or reaction after methyl thiouracil, operation contraindicated.;
do. , operation refused,
do. , operation not offered.
Treatment of election.
Euthyroid.
Improved.
Hypothyroid.
Uodular goitre. (Glands diffuse unless specified
